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Abstract  
 
Interleukin (IL) -6 is a pleiotropic cytokine that is involved in the regulation of immune reactions, 
hematopoiesis, bone metabolism and inflammation. Deregulation of IL-6 has been shown to be 
involved in several inflammatory and autoimmune disorders, including rheumatoid arthritis, 
Castleman’s disease and Crohn’s disease. Therefore, interception of the IL-6 signaling pathway 
represents an interesting therapeutic target for the treatment of these diseases.  
VAF347 is a novel low molecular weight immunomodulator which has been shown to selectively 
block IgE synthesis in human B cells and to inhibit IL-6 production in human monocyte-derived 
dendritic cells. This study was designed to identify the molecular target(s) of VAF347 that lead to 
inhibition of IL-6 synthesis. Similar to primary cells, VAF347 inhibits IL-4 and GM-CSF as well as 
PMA induced IL-6 production in the human monocytic cell line Monomac1. We demonstrate, that 
the aryl hydrocarbon receptor (AhR) is the functionally relevant target for inhibition of IL-6 
response by VAF347. The AhR is responsible for mediating the biological activity of VAF347 in 
Monomac1, since 1) other AhR ligands display an identical activity profile, 2) ectopic over-
expression of a trans-dominant negative AhR protein abolishes VAF347 activity, and 3) silencing of 
AhR gene expression renders Monomac1 resistant to VAF347. 
Furthermore, VAF347 inhibits the activation of an IL-6 promoter reporter gene construct and blocks 
the binding of the transcription factor NF-IL6, which is thought to be one of the main factors 
involved in IL-6 regulation, to the IL-6 promoter. Over-expression of wild type NF-IL6 partially 
abolishes VAF347 activity. These findings showed that VAF347 mediates its inhibitory effect at the 
transcriptional level by inhibiting the interaction of NF-IL6 with its binding site on the IL-6 
promoter.  
Collectively, these data identify the AhR as the functional target of VAF347. Given the fact that  
IL-6 deregulation is involved in the pathology of several inflammatory and autoimmune diseases, 
targeting the AhR may provide a new tool for the treatment of these diseases.  
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Kurzfassung  
 
Interleukin (IL) -6 ist ein pleiotropes Zytokin das sowohl an der Regulation von Immunreaktionen, 
der Hämatopoese, dem Metabolismus des Knochens als auch an Entzündungsreaktionen beteiligt 
ist. Eine deregulierte Produktion von IL-6 ist bei mehreren Entzündungs- und 
Autoimmunerkrankungen gefunden worden, wie etwa bei Gelenkrheumatismus, Morbus Castleman 
oder Morbus Crohn. Deshalb stellt die Unterbrechung des IL-6 Signalweges ein interessantes 
therapeutisches Angriffsziel für die Behandlung dieser Krankheiten dar. 
Es wurde bereits gezeigt, dass VAF347 als ein neuer niedermolekularer Immunmodulator sowohl 
spezifisch die Immunglobulin-E Synthese von humanen B-Zellen, als auch die IL-6 Produktion von 
humanen Dendritischen Zellen monozytären Ursprungs inhibiert.  
Diese Studie wurde gestaltet, um das (die) molekulare(n) Ziel(e) von VAF347, das zur Inhibierung 
der IL-6 Produktion führt, zu identifizieren. Ähnlich wie bei primären Zellen inhibiert VAF347 die 
von IL-4 und GM-CSF als auch die von PMA induzierte IL-6 Produktion in der humanen 
monozytären Zelllinie Monomac1. Es wird gezeigt, dass der Aryl Hydrocarbon Rezeptor (AhR) das 
funktionell bedeutende Target für die Inhibition der IL-6 Produktion durch VAF347 ist. Der AhR 
ist für die biologische Aktivität von VAF347 in Monomac1 Zellen verantwortlich, da 1) andere 
AhR Liganden ein ähnliches Aktivitätsprofil zeigen, 2) ektopische Überexpression eines 
transdominant negativen AhR Proteins die biologische Aktivität von VAF347 aufhebt und 3) die 
Stilllegung des AhR Gens Monomac1 Zellen resistent gegen VAF347 macht.  
Darüber hinaus inhibiert VAF347 die Expression eines IL-6 Promoter Reporter-Gen Konstrukts und 
blockiert die Bindung des Transkriptionsfaktors NF-IL6, welcher als einer der Hauptfaktoren für 
die Regulation der IL-6 Expression angesehen wird, an den IL-6 Promoter. Die Überexpression des 
Wildtyp NF-IL6 Proteins hebt teilweise die Aktivität von VAF347 auf. Diese Ergebnisse 
demonstrieren, dass VAF347 seinen inhibitorischen Effekt auf transkriptioneller Ebene ausübt, da 
die Interaktion von NF-IL6 mit dessen Bindungsstelle im IL-6 Promoter verhindert wurde. 
Zusammenfassend identifizieren diese Daten AhR als das funktionell entscheidende Target von 
VAF347. Da die Deregulation von IL-6 am Krankheitsbild mehrerer inflammatorischer- und 
Autoimmunerkrankungen beteiligt ist, könnte das Targeting von AhR eine neue Möglichkeit zur 
Behandlung dieser Krankheiten darstellen.  
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Abbreviations  
 
aa   amino acid(s) 
AhR   aryl hydrocarbon receptor 
AhRR  aryl hydrocarbon receptor repressor 
ARNT  aryl hydrocarbon receptor nuclear translocator 
Amp   ampicillin 
bp   base pair(s) 
ChIP   chromatin immunoprecipitation 
CYP1A1  cytochrome P450 1A1 
DC(s)  dendritic cell(s) 
DNA   deoxyribonucleic acid 
ds   double stranded 
EtOH  96% Ethanol 
GFP   green fluorescent protein 
GM-CSF  granulocyte macrophage colony-stimulating factor 
HRP   horse radish peroxidase 
IgE   Immunoglobulin-E  
IL-6   Interleukin-6 
JAK(s)  Janus Kinase(s) 
kDa   kilo Dalton 
MAPK  mitogen-activated protein kinase 
MM1   Monomac1 
PBS   phosphate buffered saline 
PKC   protein kinase C 
PMA   phorbol 12-myristate 13-acetate 
RNA   ribonucleic acid 
RT   room temperature 
ss   single stranded 
STAT  signal transducer and activator of transcription 
TCDD  2,3,7,8-tetrachlorodibenzo-p-dioxin 
TH17   Interleukin-17 producing T cell 
Treg   regulatory T cell 
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1. Introduction  
 
1.1 The immune system: cytokines and their function 
The development of an effective immune response involves the interaction of multiple cell types 
including myeloid cells and lymphocytes. The complex interactions among these cells are in part 
mediated by cytokines. Cytokines are relatively small regulatory proteins that are secreted from 
cells of innate and adaptive immunity as well as various other cell types in response to a number of 
stimuli. On one hand, a subgroup of these proteins stimulate the growth and differentiation of 
various cells during immune homeostasis, while on the other hand, cytokines facilitate the 
activation and differentiation of effector cells both during the innate and adaptive phases of immune 
responses against foreign antigens such as bacteria, viruses or self-antigens.  
Binding of cytokines to specific receptors on the membrane of target cells leads to the activation of 
diverse signal-transduction pathways which ultimately lead to altered gene expression.  
In recent years cytokines and their receptors have become important targets for specific antagonists 
in various immune and inflammatory diseases. One of these cytokines that is considered as such a 
target, due to its pro-inflammatory functions is the cytokine Interleukin-6 (IL-6). IL-6 is a 
pleiotropic cytokine that is involved in the regulation of immune reactions, hematopoiesis, bone 
metabolism and inflammatory state. The overproduction of IL-6 has been implicated in the 
pathology of several inflammatory and autoimmune disorders, including rheumatoid arthritis, 
Crohn’s disease, Castleman’s disease and systemic-onset juvenile idiopathic arthritis. Therefore 
interception of the IL-6 signaling pathway has become an interesting target for the treatment of 
these diseases.  
 
1.1.1 The discovery of Interleukin-6 
The history of nomenclature reflects the diverse biological functions of this cytokine: IL-6 was 
initially identified as a T cell-derived B-cell differentiation factor that induces B-cells to 
differentiate into antibody-producing cells (1), and was therefore first termed B-cell stimulatory 
factor-2 (BSF-2). The complementary DNA of BSF-2 was cloned in 1986 (2). Following its 
discovery, BSF-2 was found to be identical to the 26 kDa protein (3), an interferon-β2 protein (4), a 
hybridoma/plasmacytoma growth factor (5,6) and a hepatocyte-stimulating factor (7). Later these 
names were unified as IL-6.  
 
1.1.2 Structure and expression of Interleukin-6 
The human IL-6 gene contains four introns and four exons and maps to chromosome 7p21 (8). With 
a length of 212 amino acids (aa), human IL-6 has a molecular mass of 21 to 28 kilo Dalton (kDa) 
Introduction 
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and contains two N-glycosylation sites (2). Four cysteine residues are conserved in the central 
portions of human and murine IL-6, which are not necessary for IL-6 activity (9). Human IL-6 
shows a sequence homology of 65% at the DNA level and 42% at the protein level compared with 
murine IL-6 (10).  
IL-6 is not constitutively expressed in the human body, but is induced by a large number of multiple 
stimuli including bacterial and viral infections, microbial components such as lipopolysaccharide 
(LPS) and different cytokines (11). IL-1β, TNF-α and IFN-γ have been shown to induce IL-6 
expression in many cell types including T-cells, B-cells, monocytes, endothelial cells, fibroblasts 
and several kinds of tumor cells.  
 
1.1.3 The Interleukin-6 promoter 
A series of transcription factors have been described to contribute to the complex regulation of the 
IL-6 gene. Their interactions may vary depending on the extracellular stimuli as well as the cell 
type. So far, several functional cis-regulatory elements in the human IL-6 promoter have been 
identified, including nuclear factor-kappa B (NF-κB) (position -62 to –49 relative to the 
translational start codon), nuclear factor-IL6 (NF-IL6) (-144 to -132), cAMP response element-
binding protein (CREB) (-152 to -145) and activator protein 1 (AP-1) (-271 to –263) binding sites 
(Figure 1.1.3.1). 
NF-κB is a member of the Rel family of transcription factors that form homo- or heterodimers 
through the Rel homology domain (12). In resting cells, NF-κB is located in the cytoplasm bound to 
a member of the family of inhibitors of κB (IκBs). Upon activation of cells by diverse stimuli, IκBs 
become phosphorylated and are rapidly degraded. The degraded IκBs can no longer bind to NF-κB 
which is therefore released and translocated to the nucleus where it binds to its specific DNA 
recognition site and contributes to the transcriptional activation of multiple genes.  
NF-IL6, also known as CCAAT/enhancer binding protein beta (C/EBP β), belongs to the family of 
C/EBP transcription factors which are characterized by a basic leucine-zipper structure which is 
responsible for homo- or heterodimerization (13). In primary cells, NF-IL6 is usually expressed at 
low levels and is strongly induced upon stimulation of cells by TNF-α, IL-1β or LPS. In contrast, 
NF-IL6 is constitutively expressed in many cell lines. Phosphorylation of NF-IL6 has been shown 
to increase its transcriptional activity (14). 
Introduction 
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Figure 1.1.3.1: The human IL-6 promoter. A part of the IL-6 promoter is shown in which 
core sequences for each transcription factor binding site are indicated in bold. The start 
codon ATG for the IL-6 gene is boxed, the TATA box is bolded. The numbers on top of 
corresponding nucleotides give the position relative to the start codon ATG. 
 
 
The AP-1 transcription factors are homo- or heterodimers of basic region-leucine zipper proteins 
belonging to the Jun and Fos subfamilies (15). Since Fos proteins do not form stable dimers, they 
need to form dimers with Jun proteins to bind DNA. The members of the Jun protein family vary 
considerably in their DNA binding affinities and transactivation capacities, with c-Jun showing the 
highest activation potential (16). 
Studies in various cell types have shown that induction of IL-6 gene transcription is complex and 
involves the coordinated regulation of factors that associate with the evolutionary conserved  
NF-κB, NF-IL6 and AP-1 sites in the mouse and human IL-6 promoter (17-21).  
 
 
...GTCAAGACATGCCAAAGTGCTGAGTCACTAAT
AAAAGAAAAAAAGAAAGTAAAGGAAGAGTGGTTCTGCTTCTTAGCGC
TAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTAGTTGTGTCT
TGCGATGCTAAAGGACGTCA CATTGCACAATCTTAATAAGGTTTCC
AATCAGCCCCACCCGCTCTGGCCCCACCCTCACCCTCCAACAAAGAT
TTATCAAATGTGGGATTTTCCCATGAGTCTCAATATTAGAGTCTCAA
CCCCCAATAAATATAGGACTGGAGATG
+1-17 -10
TATA box
TATA box
-62 -49 -39 -34
-152 -145
-271 -263
-144 -132
NF-κB
CREB NF-IL6
AP-1
-290
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1.1.4 Cellular signaling and regulation of Interleukin-6 
IL-6 has a unique receptor system (22). The IL-6 receptor consists of two functional membrane 
proteins: an 80 kDa IL-6 binding chain (IL-6R, IL-6R α-chain, CD126) (23) and a 130 kDa  
signal transducer (gp130, IL-6R β-chain CD130) involved in IL-6 signal transduction (24,25). The 
80 kDa IL-6 receptor can exist in transmembrane form or in soluble form. The transmembrane form 
has a short intracytoplasmatic region consisting of 82 aa, that lacks tyrosine-kinase domains and 
does not have an enzymatic role in IL-6 signaling. 
Binding of IL-6 to the membranous IL-6 receptor brings the intracellular segments of two IL-6R 
chains in close proximity, thus permitting the association of the intracellular IL-6R segments with 
the 130 kDa glycoprotein (Figure 1.1.4.1). This is thought to induce the formation of a multimeric 
complex consisting of two IL-6 molecules bound to two IL-6R proteins and two gp130 molecules 
bound to the intracytoplasmatic segments of the two IL-6R proteins.  
On the other hand, the soluble form of IL-6R, which is produced by cleavage of the membranous 
IL-6R or by alternative splicing, can bind IL-6. A complex of two IL-6 molecules bound to two 
soluble IL-6R proteins forms a complex with two gp130 proteins. This complex is able to transmit 
signals in a process called trans-signaling (26). 
Dimerization of gp130 proteins transduces a signal to activate members of the JAK tyrosine kinases 
(Janus family tyrosine kinases). JAKs represent a family of four non-receptor tyrosine kinases, 
comprising the members JAK1, JAK2, JAK3 and Tyk2, which selectively phosphorylate the signal 
transducer and activator of transcription (STAT) proteins thus leading to their activation. In the case 
of IL-6R signaling, JAKs recruit and induce tyrosine phosphorylation of STAT3, which is 
translocated to the nucleus in its phosphorylated form and induces gene expression. 
Overproduction of IL-6 leads to inflammation and disease, therefore this cytokine must be regulated 
to control the duration and magnitude of IL-6 response. A negative feed-back loop regulates the  
IL-6 signaling system via activation of the suppressors of cytokine signaling (SOCS) and the 
protein inhibitors of activated STATs (PIAS). Phosphorylated and thus activated STAT3 
translocates to the nucleus and induces the expression of SOCS3, which in turn binds to JAKs and 
thus suppresses gp130 signal transduction (27). PIAS are constitutively expressed negative 
regulators of STAT proteins. In the case of IL-6 signaling, PIAS3 associates specifically with 
activated STAT3 and blocks further STAT3 mediated gene transcription (28).  
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Figure 1.1.4.1: An overview of the IL-6 signaling pathway. A unique receptor system consisting of 
two functional membrane proteins mediates IL-6 signaling: an 80 kDa ligand binding IL-6 receptor 
(IL-6R) together with a 130 kDa signal-transducing chain (gp130). The IL-6R can exist in either 
membrane-bound or soluble form. The soluble IL-6R, lacking the cytoplasmatic domain is observed 
in normal serum. Soluble IL-6R is capable of transmitting signals in a process called trans-
signaling. The binding of IL-6 to IL-6R triggers receptor activation by the formation of a 
multimeric complex, consisting of two IL-6R proteins and two gp130 molecules. Receptor activation 
facilitates recruitment of JAKs, which when transphosphorylated, subsequently phosphorylate the 
gp130 tails. Phosphorylated gp130 residues recruit STAT3 proteins, which are also phosphorylated 
by JAKs. Phosphorylated and thus activated STAT3 dimerizes, translocates to the nucleus and 
induces the transcription of target genes, including acute phase proteins and its own negative 
regulator SOCS3.  
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1.1.5 Biological effects of Interleukin-6 
Originally IL-6 was described as a T-cell-derived B-cell differentiation factor. Further B-cell 
studies showed that IL-6 enhances the production of IgM, IgG and IgA in activated human  
B-cells (29). Addition of anti-IL-6 antibody to stimulated B-cells abrogates the production of these 
immunoglobulins, however anti-IL-6 antibody does not affect the proliferation of activated B-cells. 
Thus, IL-6 is thought to be essential for antibody production by activated  
B-cells but not for their proliferation. 
The effects of IL-6 are not limited to B-cells, in fact IL-6 exerts diverse functions on multiple cell 
types. In contrast to B-cells, IL-6 induces the proliferation of mitogen-activated T-cells by inducing 
both IL-2 production (30) and IL-2 receptor expression (31). In addition to the stimulation of IL-2 
synthesis and secretion, IL-6 acts synergistically with IL-2 in driving the differentiation of human 
T-cells into cytotoxic T-cells (32). Furthermore, IL-6 acts as a terminal differentiation factor for 
macrophages (33). 
IL-6 is also involved in the acute phase response to inflammation or tissue injury which is 
characterized by increased serum levels of acute phase proteins such as fibrinogen and haptoglobin, 
and decreased serum levels of albumin. The acute phase response is a consequence of liver cells 
responses to inflammatory signals. Studies in human hepatocytes show that IL-6 induces the 
expression of a variety of acute phase proteins (34), including  
C-reactive protein, fibrinogen, α1-antitrypsin and serum amyloid A, while it suppresses the 
synthesis of albumin (35,36). Thus, IL-6 is considered as a major mediator of the acute phase 
response. 
IL-6 acts on hematopoietic stem cells synergistically with IL-3 to induce the formation of 
multilineage blast cell colonies (37). Soluble IL-6 receptor is involved in bone metabolism by 
triggering osteoclast differentiation (38). Furthermore, IL-6 acts on the differentiation of 
megakaryocytes to produce platelets (39) and has been shown to support the survival of cultured 
cholinergic neurons (40,41).  
 
1.1.6 Interleukin-6 in rheumatoid arthritis 
Overproduction of IL-6 is involved in the pathology of a series of inflammatory and autoimmune 
diseases including rheumatoid arthritis (RA), Crohn’s disease, Castleman’s disease and systemic 
lupus erythematosus. 
RA is a chronic inflammatory disease that is characterized by inflammation and cellular 
proliferation in the synovial lining of joints, that can ultimately lead to irreversible destruction of 
cartilage and periarticular bone. Abnormal laboratory findings in RA patients show elevated levels 
of acute-phase reaction related proteins and the emergence of autoantibodies. Although the etiology 
Introduction 
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and pathogenesis of this disease still remain incompletely understood, it is clear that cytokines play 
a key role in the activation of synovial cells. The most important cytokines in RA are the  
pro-inflammatory cytokines TNF-α and IL-1β. Both cytokines stimulate the production of IL-6 
from synovial cells in RA patients in vitro (42). Elevated levels of IL-6 are constantly observed in 
RA patients (43,44) and moreover, correlations between elevated IL-6 levels in sera or synovial 
fluid and the grade of disease activity have been established (45,46). A polymorphism in the IL-6 
promoter which seems to be associated with an increase in disease susceptibility and activity has 
been noted in some RA patients (47). It is believed that the biological activity of IL-6 contributes to 
some symptoms of RA such us the induction of acute phase proteins (35), autoantibody production, 
induction of osteoclasts (38) and increased platelet numbers (39). 
Therefore, inhibition of IL-6 signaling constitutes a new therapeutic tool for the treatment of this 
disease. So far, the only anti-IL-6 strategy in humans has been the use of tocilizumab, a humanized 
murine anti-human IL-6R antibody (48). In vitro, tocilizumab has been confirmed to bind both the 
soluble and membrane-bound forms of IL-6R and to inhibit the pro-inflammatory activity of IL-6 
by inhibiting the binding of IL-6 to its receptor (49).  
A series of clinical studies using tocilizumab in RA patients showed that administration of anti-
IL6R antibody significantly improved all measures of disease activity based on the American 
College of Rheumatology criteria (50,51).  
In other clinical trials tocilizumab has been shown to be therapeutically effective for other 
inflammatory diseases such as Castleman’s disease (52,53), juvenile idiopathic arthritis (54) and 
Crohn’s disease (55). Since IL-6 is a physiologically essential cytokine, adverse effects following 
anti-IL-6 therapy may occur. The long term safety of humanized anti-IL-6R therapy remains to be 
carefully examined.  
 
1.2 Dendritic cells and their functions 
Dendritic cells (DCs) are antigen-presenting cells that are specialized in the activation of naive  
T-cells and the initiation of an immune response. They originate from hematopoietic stem cells and 
can be characterized as immature or mature DCs as defined by the expression of phenotypic cell 
surface markers (56). Immature DCs are typically characterized by the lack of co-stimulatory 
molecules CD80 and CD86. They are located in the peripheral tissues, where they are adapted to 
capture antigen and alert for multiple danger signals such as inflammatory cytokines, microbial 
products and cytoplasmatic/nuclear molecules released as a consequence of cellular necrosis. 
Exposure to these factors triggers DC maturation, a process that leads to expression of high levels 
of the co-stimulatory molecules CD80, CD86 and CD40, the acquisition of high surface levels of 
major histocompatibility complex (MHC) II as well as the production of a broad panel of cytokines 
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including TNF-α, IL-6, IL-10 and IL-12. Subsequently, mature DCs leave the peripheral tissues and 
migrate to the T-cell rich areas of draining lymphoid organs where they activate antigen-specific  
T-cells. 
During the process of antigen-presentation, DCs are also activated via the interaction of CD40 with 
CD40 ligand expressed on T-cells and thereby produce IL-12 and IL-6. Multiple studies have 
shown that DC-derived IL-12 drives polarization of naïve CD4+ T-cells towards a  
T-helper 1 (TH1) type, while IL-6 is involved in TH2 polarization (57) and has been shown to 
impede TH1 responses (58). Recently, it has been shown that IL-6 produced by DCs from Lupus-
prone mice inhibits the suppressive function of CD4+ CD25+ regulatory T-cells (59).  
T-regulatory (Treg) cells control the autoreactive components of the immune system (60) and 
suppress pathogenic autoimmunity in healthy individuals. Therefore impaired Treg cells 
development and functions have been shown to be the cause of several autoimmune diseases (61). 
 
1.3 VAF347, a novel low molecular weight immunomodulator 
VAF347 was originally identified in a screening campaign designed for the identification of 
compounds that inhibit IgE production in human B-lymphocytes in an isotype-specific fashion. The 
initiation of IgE synthesis in B-lymphocytes requires the TH2-cell derived cytokine IL-4 and direct 
T-cell/B-cell contact which involves interaction of CD40 ligand on T-cells and CD40 on B-cells. 
Together these two signals induce B-cell activation and trigger the differentiation into plasma cells 
which undergo immunoglobulin class switching (62) to secrete IgE. VAF347 inhibits IL-4 + anti-
CD40 as well as IL-13 + anti-CD40 induced IgE production in purified human B-cells in a dose-
dependent fashion with an inhibitory concentration (IC50) of approximately 1 nM (63). In contrast, 
VAF347 does not inhibit the production of IgG isotypes or IgA in B-cells, demonstrating that 
VAF347 inhibits IgE production in an isotype-specific fashion. 
Further biological profiling of VAF347 in other cell types known to be relevant in atopic disease 
showed that VAF347 had no effect on T-cells, mast cells, endothelial cells, keratinocytes and 
fibroblasts. In contrast to these cells, VAF347 inhibits human monocyte-derived DCs in their 
function to induce T-cell proliferation and cytokine production (63). VAF347 does not directly act 
on T-cells since activation of T cell proliferation and IL-2 production by antibodies to CD3 and 
CD28, in the absence of DCs are not affected. Furthermore, VAF347 was shown to downregulate 
the induced expression of CD86 and human leukocyte antigen (HLA)-DR on the cell surface of 
human monocyte-derived DCs. Thus, VAF347 has inhibitory effects on DC differentiation and 
maturation as well as the antigen presenting and T-cell stimulatory capacity of these cells. In 
addition, VAF347 was shown to inhibit the production of IL-6 in mature DCs in a dose-dependent 
fashion with an IC50 of 1nM. The synthesis of other soluble products like the chemokines MDC or 
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TARC, known to be induced in mature DCs, was not affected. Due to the specific inhibition of  
IL-6, VAF347 does not act as a general inhibitor of DC maturation suggesting that the compound 
targets a specific signaling pathway(s) induced by the maturation stimuli. 
In vivo profiling of the biological effects of VAF347 showed that in an antigen-induced mouse 
model of eosinophilic lung inflammation, VAF347 blocked lung eosinophilia, mucus hyperplasia 
and serum IgE levels (63). In these experiments VAF347 was superior to suplatast tosilate, a 
marketed compound (Taiho) which has been used since 1995 for the treatment of patients with 
asthma. Suplatast tosilate was considered a relevant mechanistic comparator based on the proposed 
mode of action as an inhibitor of T-cell derived IL-4 and IL-6 production (64), thus resulting in 
suppression of IgE synthesis and block of pulmonary inflammation in vivo (65). The anti-
inflammatory effects of VAF347 in vivo are most likely mediated by the immunoregulatory role of 
VAF347 on DCs since allergic lung inflammation was also inhibited in B-cell-deficient mice (63).  
A novel study with VAG539, a water-soluble derivative of VAF347, demonstrated that oral 
administration of VAG539 promotes long-term graft acceptance and active tolerance in Balb/c mice 
transplanted with MHC-mismatched pancreatic islet allografts (66). Tolerance induction was due to 
immuno-modulation of DCs since transfer of tolerant DCs into naive mice followed by allogeneic 
islet transplantation prevented graft rejection. Furthermore, cell therapy with in vitro VAF347 
treated bone marrow derived DCs also led to strongly decreased numbers of rejected islets. DCs 
probably were not the only cell type responsible for tolerance induction since treatment with 
VAG539 resulted in increased frequency of splenic CD4+ T-cells expressing CD25 and Foxp3, 
markers associated with Treg cells. The transfer of CD4+ CD25+ Treg cells from these mice into 
newly transplanted mice promoted graft acceptance.  
 
1.3.1 Identifying the molecular target(s) of VAF347 
The molecular target(s) of VA347 have not been identified so far. As an approach to better 
understand which pathways may be regulated by VAF347, immature monocyte derived DCs were 
activated by engagement of CD40 in the presence or absence of VAF347 for 8 hours before the 
genome wide expression pattern profile was determined by RNA chip analysis (67). Among the top 
15 down–regulated genes in VAF347 treated DCs was the IL-6 gene, thus validating the RNA chip 
analysis. 
To identify genes that are known to be regulated by a common signaling pathway the top 15 
induced genes were examined. Interestingly, 3 out of the 15 top induced genes namely the aryl 
hydrocarbon receptor repressor (AHRR), cytochrome P450 1B1 (CYP1B1) and TCDD inducible 
poly(ADP-ribose) polymerase (TiPARP), are known to be regulated by aryl hydrocarbon receptor 
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(AhR) signaling. These results indicated that VAF347 may function as an activator of AhR signal 
transduction. 
 
1.4 The aryl hydrocarbon receptor (AhR) 
1.4.1 Function and structure of the AhR 
The aryl hydrocarbon receptor is a ligand-activated transcription factor that plays a central role in 
the induction of a broad range of biotransformation enzymes. AhR is found to be ubiquitously 
expressed in most cells and organs of the body (68) and is considered as the crucial factor in 
regulation of xenobiotic metabolism. Xenobiotics are innumerable chemical compounds of natural 
or synthetic origin, which are foreign to the human body, such as environmental pollutants, drugs or 
food additives. Biotransformation of xenobiotics is formally divided into three phases: in Phase I 
usually a polar moiety is introduced into the molecule. In Phase II the oxygenated products of Phase 
I are conjugated to small endogenous molecules such as glutathione, glucuronic acid, cysteine or 
acetate. Phase III describes the transmembrane export of these metabolized xenobiotics (69). 
The aryl hydrocarbon receptor belongs to the small family of basic helix-loop-helix (bHLH) 
transcription factors which also includes the transcriptional regulators Per (Period), AhR nuclear 
translocator protein (ARNT) and Sim (Single minded). All members of this protein family share a 
bHLH motif in the NH2 terminal region (Figure 1.4.1.1), which is involved in DNA binding and 
homo- or heterodimerization.  
Adjacent to the COOH-terminus of the bHLH region follows the PAS domain, which has been 
named after the first three proteins identified with this motif: the Drosophila Per protein, human 
ARNT and Drosophila Sim (70). Proteins of the bHLP/PAS family can mediate a broad range of 
diverse biochemical functions including the involvement in circadian rhythms, organ development, 
neurogenesis and metabolism. Members of the bHLH protein family have been found in mammals, 
flatworms, insects, fungi, plants and cyanobacteria (71,72). Usually the PAS domain consists of 
260-310 amino acids and contains two conserved hydrophobic repeats of 50 aa, named PAS-A and 
PAS-B, which are both involved in homo- or heteroformation. In the case of AhR the PAS domain 
facilitates heterodimerization of the AhR with its partner molecule aryl hydrocarbon receptor 
nuclear translocator (ARNT) (73). 
The ligand binding domain is located between amino acids 230 – 431 of AhR (Figure 1.4.1.1), and 
thus partially overlaps with the PAS-B region as well as the region necessary for binding of heat 
shock protein 90 (Hsp90) (74). Hsp90 interacts with parts of the PAS-B region and also with the 
bHLH-region to mask the nuclear localization signal of AhR, thus keeping the receptor in the 
cytoplasm. 
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Figure 1.4.1.1: Schematic representation of functional domains of AhR. In the NH2-
terminal region AhR contains a bHLH (basic helix-loop-helix) motif (blue box), involved in 
DNA binding and homo- or heterodimerization. Adjacent to the COOH-terminus of the bHLH 
region follows a PAS (Per-ARNT-Sim) domain (yellow box) which is considered as an 
interactive platform for homo- or heterodimer formation. A glutamine rich region at the 
COOH-terminus is shown in grey. The location of functional domains is indicated by bars. 
 
In addition, AhR contains a nuclear export signal in the second helix of the bHLH domain which is 
necessary for the nuclear export of AhR (75). The transactivation domain is broadly distributed in 
the COOH-terminal half of the AhR (Figure 1.4.1.1). Upon dimerization with ARNT, the 
AhR/ARNT heterodimer transmits its transactivation activities to general transcription factors 
through interaction with Sp1, CBP/p300, RIP140, and SRC-1 (76-79). 
 
1.4.2 Ligands of AhR 
The AhR can be activated by a broad range of diverse classes of compounds, including exogenous 
ligands such as polycyclic aromatic hydrocarbons (PAHs) and halogenated aromatic hydrocarbons 
(HAHs) as well as endogenous ligands. The prototypical ligand of AhR is 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), which belongs to the family of HAHs. HAHs are usually 
generated in industrial production or as a product of waste incineration. TCDD has been shown to 
induce a broad spectrum of biochemical and toxic effects, including the induction of drug-
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metabolizing enzymes, teratogenesis, immunosuppression, tumor promotion and the induction of 
chloracne. Part of TCDD’s toxicity is its half-life of 11 years in humans.  
PAHs compromise a large class of AhR ligands that usually contain four or more conjugated 
benzene rings. PAHs are produced as a product of combustion processes and are therefore 
commonly found in charbroiled foods, smoke exhaust and chimney soot.  
Studies which examined the binding activity of AhR ligands, using large numbers of PAHs and 
HAHs suggest that the AhR ligand binding pocket accepts planar ligands with maximal van der 
Waal’s dimensions of 14 x 12 x 5 Å (80,81). For a high binding affinity the electronic and 
thermodynamic properties of the ligand seem to be important, though the formulation of an exact 
structure has yet to be determined (81). 
Some of the ligands that bind AhR include therapeutic drugs, such as the benzimidazole 
omeprazole. Omeprazole is a proton pump inhibitor which is used for the treatment of heartburn 
and peptic ulcers. At high concentrations omeprazole induces the expression of CYP1A1, CYP1A2 
and related monooxygenases via activation of AhR (82,83). 
Since PAHs and HAHs are not commonly synthesized by living organisms but are mainly products 
of industrialization, exposure of AhR to these “novel” pollutants represents a new event from the 
standpoint of evolutionary pressure. Although PAHs may have been generated by naturally 
occurring combustion processes such as forest fires, it is believed that the emergence of the AhR 
signaling system throughout evolution was also dependent on endogenous AhR ligands. 
So far, only a few naturally occurring endogenous AhR ligands have been proposed, including the 
indigoids indirubin and indigo (84,85), the heme metabolites bilirubin and biliverdin (86), 
arachidonic acid metabolites (87,88) as well as tryptophan metabolites (89). These supposed 
endogenous ligands all have in common that they induce AhR activation in vitro only at very high 
doses, at concentrations which are normally not present in a physiologic environment (90). 
Therefore, the ability of these endogenous ligands to activate AhR and induce specific target gene 
transcription under physiological conditions remains to be determined. 
 
1.4.3 The AhR signaling pathway 
In the absence of a ligand, AhR is located in the cytoplasm associated in a complex with two 
molecules of the heat shock protein 90 (hsp90), a molecular chaperone that maintains the cytosolic 
complex (91-93), a 38kDa immunophilin-related protein named hepatitis B virus X-associated 
protein 2 (XAP2) (94-96) and the co-chaperone p23 (97) (Figure 1.4.3.1).  
Interestingly, the AhR has been shown to rapidly shuttle between the cytoplasm and the nucleus in a 
ligand independent fashion (98-100). However, the physiological significance of these observations 
remains to be elucidated.  
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Upon binding of ligand to AhR, the receptor undergoes conformational changes which ultimately 
lead to the exposure of the AhR nuclear localization signal (Figure 1.4.3.1). The whole complex is 
translocated to the nucleus where AhR dissociates from its chaperone proteins and associates with 
its partner molecule ARNT. The association of AhR and ARNT reconstitutes an active transcription 
factor that can bind to defined DNA sequences with high affinity. Binding of this heterodimeric 
transcription factor to xenobiotic-responsive elements (XRE) (101), located in the promoter region 
of AhR regulated genes finally leads to their transcription. The typical XRE core consensus 
sequence was determined to be 5’-TNGCGTG-3’.  
 
 
 
 
Figure 1.4.3.1: An overview of the AhR signaling pathway. In the absence of ligand AhR 
exists in an inactive complex with the cochaperones p23 and XAP2 as well as two molecules 
of the chaperone hsp90. Ligand diffuses into the cell and is bound by cytosolic AhR, leading 
to a conformational change that exposes the nuclear localization signal of AhR. Ligand-
bound receptor complex translocates to the nucleus, AhR is released and dimerizes with its 
partner molecule ARNT. Together the AhR/ARNT dimer binds to XREs (xenobiotic-responsive 
elements) and leads to the transcriptional activation of target genes, such as CYP1A1, 
CYP1B1 and AhRR. The dimer of ARNT and AhRR downregulates the transcriptional activity 
of AhR. AhR is exported to the cytoplasm and degraded. 
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Up to now a wide number of target genes for the AhR are known including Phase I drug 
metabolizing enzymes such as members of the cytochrome P450 family including CYP1A1, 
CYP1A2 and CYP1B1, and Phase II drug metabolizing enzymes including uridine diphosphate 
glycosyltransferase 1 family polypeptide A1 (UGT1A1), NADPH-quinone-oxidoreductase and 
glutathione S-transferase (GST)-YA subunit (69). 
AhR is also subject to negative regulation: the activation of AhR leads to the upregulation of the 
aryl hydrocarbon receptor repressor (AhRR), a basic HLH-PAS protein with high sequence 
similarity to the AhR. AhRR represses the transcriptional activity of AhR by binding to ARNT and 
by having repressive activity derived from the interaction of the AhRR/ARNT complex with XREs 
(102), thus negatively regulating AhR signaling. Following ligand-activation and nuclear export 
(75), the AhR is degraded via a 26S proteasome pathway (103-105).  
 
1.4.4 Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes 
Much of our knowledge about the multiple functions of AhR derives from studies of the 
mechanisms by which the prototypical ligand TCDD activates AhR and induces target gene 
transcription. One of the genes that was found to be activated upon TCDD exposure was CYP1A1 
(106), a member of the cytochrome P450 family which consists of 57 members in humans. 
CYP1A1 is a microsomal enzyme, predominantly found in the endoplasmatic reticulum and is 
primarily expressed in hepatic tissues in human. It catalyzes the monooxygenation of a broad range 
of xenobiotics as a part of their detoxification process, thus bioactivating many of these xenobiotics 
to carcinogens (107). For example, CYP1A1 first metabolizes benzo[a]pyrene (B[a]P) to B[a]P-4,5-
epoxide, which is then hydrolysed by the Phase II enzyme epoxide hydrolase to B[a]P-7,8 diol-9,10 
epoxide, a molecule which is highly active with DNA. Other compounds which are bioactivated in 
a similar way like B[a]P are benzo[a]anthracene and benzo[a]fluoranthene (108).  
Binding of ligand to AhR triggers its translocation to the nucleus where it partners with ARNT to 
form a heterodimeric transcription factor that binds to XRE elements in the 5’ upstream region of 
the CYP1A1 gene. For instance, in the mouse CYP1A1 promoter at least six copies of XREs were 
identified. Successful binding of AhR/ARNT heterodimer induces chromatin remodeling and 
facilitates the association of the transcription factor Sp1 to its consensus recognition site in the 
CYP1A1 promoter (109). The AhR/ARNT complex has been described to interact with Sp1, thus 
enhancing CYP1A1 transcription synergistically with Sp1 (76). Together AhR/ARNT transmit their 
transactivation activities to general transcription factors. In the case of ARNT through interaction 
with CBP/p300 and for AhR by acting as a coactivator on RIP140 and SRC-1 (77,78).  
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1.4.5 AhR-null mice 
Studies in mice lacking AhR gene expression have provided first-hand information about the 
involvement of AhR in diverse physiological processes. These animal models demonstrated that the 
AhR is essential for mediating dioxin-induced toxicity (110) and carcinogenesis (111). AhR null 
mice exhibit skin alterations (112), cardiac hypertrophy (113) and decreased accumulation of 
lymphocytes in the spleen and lymph nodes (114). The livers of mice lacking AhR gene expression 
are smaller in size and show lipid accumulation and portal fibrosis (114,115). Furthermore, AhR 
has been shown to be involved in ovary development which affects reproduction. Female AhR-null 
mice have difficulties in maintaining pregnancy and their pubs show poor numbers of survival 
during lactation and weaning (116). 
 
1.4.6 Roles of AhR in cell physiology 
The constitutive expression pattern of AhR during development and in adult tissues (117), the large 
degree of conservation among different species (118) and the phenotypic alterations in AhR-null 
mice (114,119,120), have provided strong support that AhR is involved in multiple cell physiologic 
processes independently of xenobiotic metabolism. 
One intriguing aspect of AhR biology is the ability of AhR to either promote or inhibit cell 
proliferation depending on the cell type. For example, the AhR has been shown to physically 
interact with NF-κB p65 in human breast cancer MCF-7 cells, leading to transactivation of the  
c-Myc proto-oncogene and thereby increased cell proliferation (121). Constitutive over-expression 
of active AhR in mice resulted in increased frequency of N-nitrosodiethyl-amine induced 
hepatocarcinomas (122) and tumors in the glandular stomach (123), demonstrating oncogenic 
activity of this receptor. 
On the other hand, multiple reports demonstrated that the AhR has anti-proliferative activity. 
Physical interaction of AhR with the retinoblastoma (pRb) tumor suppressor protein has been 
shown, a process leading to pRB-mediated inhibition of E2F-dependent transcription and thus 
resulting in cell cycle arrest (124).  
Activation of the AhR in mice by a single exposure to TCDD leads to profound immune 
suppression of both antibody- and cell-mediated immune responses which alters host resistance to 
many diseases (125). Also in humans exposure to TCDD has been linked to altered immune 
functions, especially when exposure occurred during fetal/neonatal development (126,127). The 
mechanisms that drive AhR dependent immune suppression became elucidated only recently by the 
observation that activation of AhR by TCDD in CD4+ T-cells leads to the generation of CD4+  
T-cells that express high levels of CD25, glucocorticoid-induced TNFR (GITR) and CTLA-4 and 
only low levels of CD62L, a phenotype associated with regulatory T cells (Treg) (128). Treg cell 
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function and differentiation are driven by the transcription factor Foxp3 (129,130). The 
development of Treg cells is closely related to the generation of IL-17 producing T cells (TH17), 
which express the transcription factor ROR-γt (131). TH17 cells are involved in the control of 
extracellular pathogens and were shown to have important roles in experimental and human 
autoimmunity (132). Treg cells are usually induced by transforming-growth factor (TGF)-β1, while 
TGF-β1 in combination with IL-6 or IL-21 has been shown to induce the differentiation of  
TH17 cells (133,134).  
Recently, activation of AhR by TCDD has been shown to induce the generation of Treg cells in mice 
that were able to suppress experimental autoimmune encephalomyelitis (EAE, a mouse model for 
multiple sclerosis) by a TGF-β1-dependent mechanism (135). In contrast, activation of AhR by  
6-formylindolo[3,2-b]carbazole (FICZ) interfered with Treg cell differentiation and instead boosted 
TH17 cell differentiation (136) and worsened EAE (135). Finally, activation of AhR signaling by 
TCDD in human synovial tissue obtained from rheumatoid arthritis (RA) patients was shown to 
induce the expression of inflammatory cytokines, an effect that was transmitted via the NF-κB and 
ERK signaling cascades (137). Therefore, exposure of RA patients to AhR activators, which are 
commonly found in normal dietary food in industrialized countries, is thought to exacerbate RA 
pathophysiology. These data demonstrate that AhR regulates both Treg and TH17 cell differentiation 
in a ligand specific fashion which could make AhR a novel target for the therapeutic manipulation 
of the immune response. 
 
1.5 Aim 
The aim of this study was to identify the molecular target(s) of VAF347 that leads to inhibition of 
IL-6 expression in Monomac1 (MM1) cells. Similar to human monocyte-derived DCs, VAF347 
inhibits expression of IL-6 in MM1, however the molecular mechanism is unknown. 
Overproduction of IL-6 is critically involved in several inflammatory and autoimmune diseases 
including rheumatoid arthritis, Crohn’s disease, Castleman’s disease and juvenile idiopathic 
arthritis. Therefore, understanding the molecular mechanism(s) by which VAF347 interferes with 
IL-6 expression might provide new insights for the treatment of these diseases. 
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2. MATERIALS AND METHODS  
All work was done in the Novartis Institutes for Biomedical Research (NIBR), Vienna, Austria in 
the laboratory of Univ.-Doz. Dr. Maximilian Woisetschläger. If not mentioned otherwise all 
reagents/solutions were supplied by the Nährbodenküche of the NIBR. 
 
2.1 Standard Methods  
2.1.1 Qiagen Plasmid Miniprep 
A single TG1 E. coli colony from a freshly streaked LB-Ampicillin selective plate was used to 
inoculate 2ml of Luria-Bertani (LB)-Broth medium, containing the antibiotic ampicillin at a 
concentration of 100µg/ml and was shaken for 16h at 37°C. 1.5ml of this dense bacteria suspension 
were transferred into an eppendorf tube and harvested by centrifugation for 5min at 5.000rpm in an 
Eppendorf Centrifuge. After removal of the supernatant the pellet was resuspended in 250µl of 
resuspension buffer P1, supplemented with 250µl of Lysis buffer P2 and turned over a few times to 
mix. After the addition of 350µl of neutralisation buffer P3 the tube was inverted immediately 4-6 
times and then centrifuged for 10min at 13.000rpm. The complete supernatant was transferred onto 
a QIAprep 2ml collection tube and centrifuged for 1min at 13.000rpm. The eluate was discarded, 
0.5ml of washing buffer PB were added onto the column and the tube was again centrifuged for 
1min at 13.000rpm. The eluate was discarded, 0.75ml of buffer PE were added and the tube was 
centrifuged for 1min at 13.000rpm. After the eluate was discarded completely, the tube was 
centrifuged for 1 min at 13.000rpm to remove residual wash buffer. The dry spin column was put 
into a fresh eppendorf tube, 50µl of nuclease free H2O was added to the center of the column and 
incubated for 1min at RT. The DNA was eluted by centrifugation for 1min at 13.000rpm. The 
eluate in the tube contained the plasmid-DNA which was stored at –20°C until use. 
 
2.1.2 Qiagen Plasmid Maxiprep 
A single TG1 E. coli colony from a freshly streaked LB-Ampicillin selective plate was picked to 
inoculate a starter culture of 2ml Luria-Bertani (LB)-Broth medium containing the antibiotic 
ampicillin at a concentration of 100µg/ml. This starter culture was incubated for about 8h at 37°C 
with vigorous shaking. 500µl of this culture were used to inoculate 250ml LB-medium, with 
100µg/ml ampicillin added and the culture was shaken for 16h at 37°C. The dense bacterial culture 
was transferred into a GS3 plastic container and was harvested by centrifugation for 10 minutes at 
6000rpm in a Sorvall Centrifuge (RC-5C, Sorvall Instruments) at 4°C. The supernatant was 
removed and the pellet was resuspended in 10ml of Buffer P1 (Resuspension Buffer containing 
RNase A). After the pellet was completely resuspended, 10ml of Buffer P2 (Lysis Buffer) were 
added, mixed gently by swirling and incubated for 5min at RT. After the addition of 10ml of chilled 
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Buffer P3 (Neutralisation Buffer) and immediate mixing, the complete lysate was poured into the 
barrel of the QIAfilter Cartridge, which has been closed with a cap on its outlet noozle before, and 
left for 20min at RT. In the meantime a QIAGEN-tip 500 was equilibrated by applying 10ml Buffer 
QBT and allowing the column to empty by gravity flow. After the incubation of the lysate, the cap 
from the QIAfilter Cartridge outlet noozle was removed. The supplied plunger was gently inserted 
into the QIAfilter Cartridge and the lysate was directly filtered onto the previously equilibrated 
QIAGEN-tip 500. The cleared lysate was allowed to enter the resin by gravity flow. The QIAGEN-
tip 500 was washed twice with 30ml buffer QC. Afterwards the DNA was eluated with 15ml Buffer 
QF (Elution Buffer) into a SS34 tube and precipitated by adding 10.5ml RT-Isopropanol (Merck). 
After mixing the precipitated DNA was centrifuged immediately at 15.000rpm for 30min at 4°C in 
the SS34 rotor. After the supernatant was carefully removed, 5ml of room temperature (RT) 70% 
ethanol were added onto the pellet to remove precipitated salt. Then the tube was centrifuged at 
15.000rpm for 10 minutes at 4°C. The supernatant was removed completely and the pellet was air-
dried for 5 min and redissolved in 400µl nuclease free H2O. The DNA concentration was first 
measured at 260/280nm in a Biophotometer (Eppendorf) and afterwards diluted to a final 
concentration of 1µg/µl and stored at –20°C until use (see 2.1.3). 
 
2.1.3 DNA-Concentration Measurement 
2µl of DNA solution (in nuclease free H2O) were diluted 1:50 with nuclease free H2O in an 
Eppendorf UVette and measured in a photometer (Eppendorf) at 260nm and 280nm after calibration 
with nuclease free H2O alone as blank. And optical density OD260=1 equals 50µg/ml dsDNA, 
meaning that a measured OD of 0.2 (of a 1:100 dilution) gives a concentration of 1µg/µl. 
 
2.1.4 Agarose gel electrophoresis 
All DNA gel seperations were done on a 1% agarose gel, run in 1xTBE. Ethidium bromide (Sigma-
Aldrich) was added to make DNA visible under UV-light. Usually 1g of agarose (GIBCO) was 
heated to 100°C in 1xTBE, cooled down to 60°C and then 6µl ethidium bromide were added. DNA 
samples were mixed with 10xBlue Juice Gel loading buffer (Invitrogen) before loading onto the gel. 
The 100 base pairs (bp) ladder (Invitrogen) was used as size marker. All gels were run using the 
BioRad Electrophoresis Power Supply Unit, for 45min at 80V. 
 
2.1.5 QIAquick Gel Extraction Kit 
DNA was visualized with ethidium bromide on a 1% agarose gel, run in 1xTBE. The DNA 
fragment was cut out from the agarose gel with a clean, sharp scalpel and transferred into a 1.5ml 
Eppendorf tube. After the gel slice was weight, 3 volumes of Buffer QG were added to 1 volume of 
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gel (for example 0.3ml of Buffer QG were added to 0.1g gel slice) and incubated for 10 min on a 
heating block at 50°C. To ensure that the agarose was dissolved completely the tube was shaken 
every 3 minutes during heat incubation. After the gel slice had dissolved completely, 1 gel volume 
of isopropanol (Merck) was added to the sample and mixed. To bind DNA, the complete solution 
was transferred on a QIAquick column and centrifuged for 1 min at 13.000rpm. After the flow-
through was discarded, 0.5ml of Buffer QG were added to the QIAquick colum and centrifuged 
again for 1 min at maximum speed. Flow-through was discarded and 0.75ml of wash Buffer PE 
were added to the QIAquick column and centrifuged for 1 min at 13.000rpm. After complete 
removal of flow-through the QIAquick column was again centrifuged for 1 min at maximum speed 
to remove residual wash buffer. The QIAquick column was placed in a clean 1.5ml Eppendorf tube 
and 10µl of nuclease free H2O were added to the centre of the QIAquick membrane. To elute DNA, 
the Eppendorf tube was centrifuged for 1 min at 13.000 rpm. Eluted DNA was ready for further use 
e.g. enzyme restriction, ligation or transformation. 
 
2.2 Generation of templates usable for RT-PCR  
2.2.1 Absolutely RNA RT-PCR Miniprep Kit (Stratagene) 
Suspension cells were harvested by centrifugation at 1300rpm for 7 min, medium was removed 
completely and the cell pellet was lysed in an appropriate amount of Lysis Buffer, usually 400µl 
Lysis Buffer for 1x106 cells. Before use 0.7µl β-Mercaptoethanol/100µl Lysis Buffer were added, 
then the cells were lysed. The cell pellet was completely homogenized by vortexing and repeated 
pipetting. Up to 700µl of this homogenate were transferred to a Prefilter Spin Cup that was seated 
in a 2-ml receptacle tube and the cap was snapped onto the spin cup. The tube was centrifuged for 5 
min at 13.000 rpm in an Eppendorf Centrifuge. The spin cup was removed and discarded, only the 
filtrate was retained. An equal volume of 70% ethanol was added to the filtrate, and the tube was 
vortexed thoroughly for at least 5 seconds. Up to 700µl of this mixture were transferred to an RNA 
Binding Spin Cup that was seated in a fresh 2-ml receptacle tube. The tube was centrifuged for 
1min at maximum speed. The flow-through was discarded and this step was repeated for the 
remaining lysate-ethanol mixture. 
After the lysate had been loaded onto the RNA Binding Spin Cup, 600µl of 1xLow-Salt Wash 
Buffer were added onto the column, the cap of the tube was snapped and the tube was centrifuged 
for 1 min at maximum speed. The flow-through was discarded and the tube was centrifuged for two 
further minutes to allow the spin cup to dry. In the mean time the DNase solution was prepared by 
gently mixing of 50µl DNAse digestion buffer with 5µl of reconstituted RNase-free DNAseI. The 
DNase solution was added directly onto the fibre matrix inside the spin cup, and the tube was 
capped. Each sample was incubated for 15 min at 37°C in an air incubator to allow complete DNase 
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digestion. After this incubation step 600µl of 1x High-Salt Wash Buffer were added to the spin cup 
and the tube was centrifuged for 1 min at maximum speed. Again the flow-through was discarded, 
and 600µl of 1x Low-Salt Wash Buffer were added onto the spin cup. The tube was centrifuged for 
1 min at maximum speed, flow-through was discarded and 300µl of 1x Low-Salt Wash Buffer were 
added onto the spin cup. The tube was centrifuged for 2 min at maximum speed to allow the RNA 
binding membrane to dry. The spin cup was then transferred to a clean and RNase free 1.5ml 
Eppendorf tube. Finally 100µl of Elution Buffer (supplied in the Kit) were added directly onto the 
centre of the fiber matrix inside the spin cup. The tube was capped and incubated for 2 min at room 
temperature. Then the tube was centrifuged for 1 min at maximum speed to elute RNA. The 
purified RNA was quantified by measuring the optical density (2.2.2) and stored immediately at -
80°C until further use. 
 
2.2.2 RNA-Concentration Measurement 
2µl of RNA solution (in nuclease free H2O) were diluted 1:50 with nuclease free H2O in an 
Eppendorf UVette and measured in a photometer (Eppendorf) at 260nm after calibration with 
nuclease free H2O alone as blank. And optical density OD260=1 equals 40µg/ml ssRNA, meaning 
that a measured OD260 of 0.1 (of a 1:100 dilution) gives a concentration of 4µg/ml RNA. 
 
2.2.3 iScript cDNA Synthesis 
The cDNA synthesis was performed with the iScript cDNA Synthesis Kit (Bio Rad) as suggested 
by the manufacturer. 0.7µg of RNA were diluted to a volume of 15µl with nuclease free H2O and 
mixed with 4µl of 5x iScript Reaction Mix. Then 1µl of the enzyme Reverse Transcriptase was 
added to each sample. The samples were put in a Mastercycler gradient (Eppendorf) using the 
conditions 5 min at 25°C, 30 min at 42°C and 5 min at 85°C. The cDNA was used for RT-PCR as 
described in 2.3. After use the cDNA was stored at -20°C. 
 
2.3 Quantitative Reverse Transcription Polymerase Chain reaction (RT-PCR)  
Quantitative RT-PCR reactions were performed in an ABI Prism 7700 Sequence Detector machine 
(Perkin Elmer) using 96well Optical Reaction Plates with Barcode, code 128 (Applied Biosystems). 
The Sybr-Green 2x Mix (Applied Biosystems) was used as a fluorescent dye which already 
contained all components necessary, excluding the primer and the cDNA template. Every cDNA 
template was analyzed in duplicates with the same primer pair. Therefore, maximally 4 different 
primers were distributed horizontally, each single primer covering two rows of the 96well plate 
when using 12 samples. Primers for the elongation Factor-1 (eF-1) were always included in 
every experiment for the normalization of the template.  
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A single 25µl PCR reaction, consisted of 12.5µl of the 2x Sybr-Green mix, 9.84µl of nuclease free 
H2O and 0.83µl of forward and reverse primer (100ng/µl). Routinely, this was pipetted as a 
mastermix for each template needed and then 24µl were aliquoted into the corresponding wells of 
the 96 well plate. Then 1µl of cDNA was added into the upper part of each well. After a short 
quickspin of the 96well plate, the PCR plate was fully sealed with Optical Adhesive Covers 
(Applied Bioscience). Finally a compression pad was put onto top of the sealed 96well plate with 
the grey side down. Now the 96well plate was ready for insertion into the ABI7700 machine. The 
following PCR-parameters were used: one cycle of 2min at 50°C and 10min at 95°C followed by 40 
cycles of 15sec at 95°C and 1min at 60°C with continuous data measurement. No 72°C incubation 
step normally found in a PCR was used for the quantitative PCR. For every primer pair used a 
dissociation curve PCR was performed once. This was necessary because if a primer pair would 
amplify more than one template this could not be distinguished with the fluorescence detection 
system. Therefore, afterwards the amplified products were analyzed for different dissociation 
temperatures which would indicate different reaction products. The following incubation 
parameters were used to test this: 2min at 95°C, 15sec at 60°C with a continuous temperature 
increase to 95°C over a period of 19min and 59sec and a final incubation at 95°C for 15sec. 
For calculation of the expression values, the average of the Ct values of the gene of interest were 
normalized to the average of the Ct values of the elongation Factor-1 (eF-1) with the following 
equation: 
2(Ct “eF-1”-Ct “gene of interest)x1000. One example is shown in more detail: the average of the eF-1 Ct 
values was 20.68 and the average of the Ct values of the gene of interest IL-6 was 25.48. This 
resulted in the equation 2(20.68-25.48), therefore 2-4.8 x1000 or in the end 35.89. The raw data was 
analyzed and graphs were made using the Excel program. 
Following oligonucleotides were used: 
MW1235: upstream 5´- CAGCTGACTTCATCCCTATTC-3´ and MW1236: downstream 5´- 
AGCTGGACATTGGCGTTCTCA-3´ for CYP1A1. 
MW1237: upstream 5´- GTACATCCTCGACGGCATCTC-3´ and MW1238: downstream 5´- 
GGCAAGTCTCCTCATTGAATC-3´ for IL-6. 
MW1556: upstream 5´- AGCGCAACAACATCGCCGTG-3´ and MW1492: downstream 5´- 
CTGACTCGAGCTAGCAGTGGCCGGAGGAGGCG-3´ for NF-IL6. 
MW1557: upstream 5´- CCATCAAGATCAATGGCTAC-3´ and MW1558: downstream 5´- 
ACTGGATTCCCAGGTTCTGG-3´ for NF-κB p65. 
MW1493: upstream 5´- GACTGGATCCCTGGGCACCATGATGTTCTCGGGCTTCAA-3´  
and MW1560: downstream 5´- TCGAGATGGCAGTGACCGTG-3´ for c-Fos. 
MW1495: upstream 5´- GACTGGATCCCTGGGCACCATGACTGCAAAGATGGAAAC-3´  
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and MW1559: downstream 5´- AGGTGAGGAGGTCCGAGTTC-3´ for c-Jun. 
MW1554: upstream 5´- CCAGCTCAGATGAGGAGGAG -3´  
and MW1555: downstream 5´- CAGGTCCAACAGGAACTGGT-3´ for PU.1. 
MW1247: upstream, 5’- TTTGAGACCAGCAAGTACTATGTGACT-3’ and MW1248: 
downstream 5’- TCAGCCTGAGATGTCCCTGTAA-3’ for eF-1α. Specificity of this amplicon was 
verified by using the VICTM labelled probe 5’- TCATTGATGCCCCAGGACACAGAGAC -3’. 
 
2.4 Cloning strategy of promoter reporter constructs, expression and silencing 
vectors  
2.4.1 Cloning of an Interleukin-6 promoter reporter construct 
The wild type Interleukin-6 promoter with a length of about ~800bp was cloned into the vector 
pGL3-basic (Invitrogen), resulting in a plasmid that contained the wild type Interleukin-6  promoter 
before the gene for luciferase. This plasmid was named pGL3b- IL-6 promoter.  
 
2.4.2.A. Amplification of the wild type Interleukin-6 Promoter 
The wild type IL-6 promoter was cloned as a 5’ - HindIII (Klenow filled up) and 3’ - BamHI  cut 
~820bp fragment into the vector pGL3-basic (Invitrogen). The promoter was amplified from 10ng 
human genomic DNA (Roche) using the PCR Primers MW1473 5’- 
CAGTCCATGGAAGCTTAGAGCAAAGTCCTCACTGGG-3’ containing an artificial HindIIII 
adapter (underlined) and MW1474 5’- GACTGGATCCAGATAGAGCTTCTCTTTCGTTC-3’ 
containing an artificial BamHI adapter (underlined). The Herculase Hotstart polymerase 
(Stratagene) and its corresponding 10x buffer were used in all following PCR reactions because of 
the high fidelity of this polymerase. The following parameters were used for amplification: 1min 
incubation at 95°C followed by 35 cycles of incubation for 30sec at 95°C, 30sec at 62°C and 
2.30min at 72°C. The resulting PCR products were loaded onto a 1% agarose gel, containing 
ethidium bromide and was run for 45 min at 80V (2.1.4). Under UV-light the desired bands were 
cut out with a clean scalpel and the DNA was further isolated using the QIAquick gel extraction Kit 
protocol (2.1.5).  
 
2.4.2.B. Restriction digestion of PCR products 
The isolated PCR fragment, which was eluted in 10µl nuclease free H2O (2.1.5) was first cut with  
HindIII at the 5’ site in 1xNEB2 buffer, supplemented with 1xBSA for 1h at 37°C. 1µl of dNTP’s 
(10mMol) and 1µl of Klenow Enzyme (Roche) were added to fill up the HindIII site for 20 min at 
RT. This reaction was stopped on a heating block at 75°C for 20 min. Then the appropriate volume 
of 10xBamHI buffer was added to reach a final concentration of 1xBamHI buffer in the reaction 
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volume, followed by the addition of 1µl of BamHI and incubation for 1h at 37°C. This resulted in a 
5’- filled up HindIII site and 3’- BamHI site Interleukin-6 promoter fragment. 
At the same time 0.5µg vector pGL3-basic was first cut with SmaI in 1xNEB4 buffer, supplemented 
with 1xBSA for 1h at 25°C. Then the appropriate volume of 10x NEB3 buffer was added  to reach a 
final concentration of 1x NEB3 in the reaction volume, followed by the addition of 1µl of BglII and 
incubation for 1h at 37°C.  
The digested PCR fragment and the restricted vector were both loaded onto a 1% agarose gel, after 
gel run the digested fragments were isolated as described above (2.1.5). 
This pGL3-basic vector fragment and the Interleukin-6 promoter Insert (5’- HindIII, Klenow filled 
up / 3’- BamHI) were ligated as described in 2.4.2.C. Then 2µl of ligation were transformed as 
described in 2.4.2.D. Positive clones were selected after a XhoI, SacI control cut (in 1x NEB1 
buffer, supplemented with 1xBSA, 1h at 37°C) which should result in a ~800bp fragment. One 
positive clone was amplified with Qiagen Maxiprep (2.1.2). 
All enzymes, buffers and additional reagents (1xBSA) were purchased from New England Biolabs.  
 
2.4.2.C. Ligation of PCR products and vector 
1µl digested and gel-isolated vector DNA, 5-10µl of digested and gel-isolated insert-DNA, 2µl of 
10x Ligase Buffer (Roche), 1µl of T4-DNA-ligase (Roche) and nuclease free H2O up to a volume 
of 10µl were mixed together. The ligation reaction took place in a water bath at 12°C over night. As 
a negative control for ligation, one sample with vector only (without any insert) was always 
included. 
 
2.4.2.D. Transformation 
50µl of competent E. coli TG1 cells and 1-2µl of a ligation reaction (or 10ng of Qiagen Maxiprep 
purified DNA) were mixed gently and incubated on ice for 30min. After a heatshock for 90sec at 
42°C on a heat block, the cells were left on ice for further 10min. Then 900µl of LB-Broth medium, 
without antibiotics were added to the cells. After an incubation for 45min at 37°C, 100µl of the 
bacteria solution was plated out onto a LB-Amp agar plate using a trigalski spatula. The plates were 
incubated at 37°C for 16h and then stored at 4°C. DNA-Minipreps from single bacterial colonies 
were prepared (2.1.1) and analyzed by digestion with the same enzymes used for cloning (if not 
mentioned otherwise). Positive clones, containing the expected fragment, were sent to Sequiserve 
(Germany). One correct plasmid which had one mismatch with the wild type sequence of the 
Interleukin-6 promoter was afterwards amplified by maxiprep (2.1.2) to generate sufficient DNA 
for transient transfections. 
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2.4.3 Cloning of a retroviral trans-dominant negative AhR expression construct 
A trans-dominant negative version of AhR, corresponding to amino acids 1-515, was cloned into 
the retroviral vector pMX-pie, which contained an internal ribosome entry site (IRES)-GFP 
element. The pMX-pie vector was kindly provided by T. Kitamura, University of Tokyo, Tokyo, 
Japan. This plasmid was named pMX- AhR 515. 
 
2.4.3.A. Amplification of trans-dominant negative AhR 
A shorter fragment of the gene for AhR, corresponding to amino acids 1-515, was cloned as a 5’ - 
NotI (Klenow filled up) and 3’ - XhoI cut ~1550bp fragment into the vector pMX-pie and named 
pMX-pie-AhR 515. The shorter DNA fragment for AhR 515 was amplified from 1µl cDNA (2.2.3) 
of the cell line Monomac 1 (2.7.3) using the PCR Primers MW1310 5’- 
GTCAGCGGCCGCCTGGGCACCATGAACAGCAGC-3’ containing an artificial NotI adapter 
(underlined) and MW1312 5’- CTGACTCGAGGTCAATTTGCTCATGTTTCAGGATT-3’ 
containing an artificial XhoI adapter (underlined). The Herculase Hotstart polymerase (Stratagene) 
and its corresponding 10x buffer were used in all following PCR reactions because of the high 
fidelity of this polymerase. The following parameters were used for amplification: 1min incubation 
at 95°C followed by 35 cycles of incubation for 40sec at 95°C, 40sec at 62°C and 3.30min at 72°C. 
The resulting PCR products were loaded onto a 1% agarose gel, containing ethidium bromide and 
the gel was run for 45 min at 80V (2.1.4). Under UV-light the desired bands were cut out with a 
clean scalpel and the DNA was further isolated using the QIAquick gel extraction Kit protocol 
(2.1.5).  
 
2.4.3.B. Restriction digestion of AhR515 PCR product and vector 
The isolated PCR fragment, which was eluted in 10µl nuclease free H2O (2.1.5) was first cut with 
NotI at the 5’ site in 1xNEB2 buffer, supplemented with 1xBSA for 1h at 37°C. Then 1µl of 10mM 
dNTP’s and 1µl of Klenow Enzyme (Roche) were added to fill up the NotI site for 20 min at RT. 
This reaction was stopped on a heating block at 75°C for 20 min. Then 1µl of XhoI was added and 
the reaction was further incubated for 1h at 37°C. This resulted in a 5’- filled up NotI site and 3’- 
XhoI site AhR 515 fragment. 
At the same time 0.5µg vector pMX-pie was first cut with BamHI in 1xBamHI buffer, 
supplemented with 1xBSA for 1h at 37°C. Then 1µl of 10mM dNTP’s and 1µl of Klenow Enzyme 
(Roche) were added to fill up the BamHI site for 20 min at RT. This reaction was stopped on a 
heating block at 75°C for 20 min. Then 1µl of XhoI was added and the reaction was further 
incubated for 1h at 37°C. 
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The digested PCR fragment and the restricted vector were both loaded onto a 1% agarose gel, after 
gel run the digested fragments were isolated as described above (2.1.5). 
This pMX-pie vector fragment and the AhR 515 insert (5’- NotI cut, Klenow filled up / 3’- XhoI 
cut) were ligated as described in 2.4.2.C. Then 2µl of ligation were transformed as described in 
2.4.2.D. A positive clone was selected after a EcoRI, XhoI control cut (in 1x EcoRI buffer, 
supplemented with 1xBSA, 1h at 37°C) which should result in a ~1250bp fragment. One positive 
clone which had been sequenced by Sequiserve and showed no mismatch with genomic sequence of 
AhR was amplified with Qiagen Maxiprep (2.1.2). 
 
2.4.4. Cloning of a retroviral AhR gene silencing construct LMP-shAhR 
The retroviral vector constructs LMP-shAhR and LMP-shControl were kindly provided by Prof. Dr. 
H. Strobl (University of Medicine, Vienna). First, a lentiviral vector backbone encoding shRNA mir 
for the AhR gene or a non silencing shRNA mir Control were purchased from Open Biosystems. 
The coding seqeunces for either shAhR or shControl were then subcloned into the retroviral vector 
MSCV-LMP (Open Biosystems) using the EcoRI and XhoI restriction sites.  
 
2.4.5. Cloning of a retroviral NF-IL6 expression construct 
The sequence of the full length NF-IL6 protein was cloned as a 5’ - BamHI and 3’ - XhoI cut 
~1050bp fragment into the expression vector pMX-pie, resulting in the plasmid pMX-pie-NF-IL6. 
The DNA fragment for NF-IL6 protein was amplified from 1µl cDNA (2.2.3) of the cell line 
Monomac 1 (2.7.3).  
The PCR Primers MW1491 5’- GACTGGATCCCTGGGCACCATGCAACGCCTGGTGGCCTG 
-3’ containing an artificial BamHI adapter (underlined) and MW1492 5’- 
CTGACTCGAGCTAGCAGTGGCCGGAGGAGGCG-3’ containing an artificial XhoI adapter 
(underlined) were used for PCR. The Herculase Hotstart polymerase (Stratagene) and its 
corresponding 10x buffer were used for PCR. The following parameters were used for 
amplification: 1min incubation at 95°C followed by 35 cycles of incubation for 40sec at 95°C, 
40sec at 62°C and 3.30min at 72°C. The resulting PCR products was loaded onto a 1% agarose gel, 
containing ethidium bromide and the gel was run for 45 min at 80V (2.1.4). Under UV-light the 
desired band was cut out with a clean scalpel and the DNA was further isolated using the QIAquick 
gel extraction Kit protocol (2.1.5). The isolated PCR fragment, which was eluted in 10µl nuclease 
free H2O (2.1.5) and the vector pMX-pie were cut with BamHI and XhoI in 1xBamHI buffer, 
supplemented with 1xBSA and incubated for 1h at 37°C.  
The digested PCR fragment and the restricted vector were both loaded onto a 1% agarose gel. After 
gel run the digested products were isolated as described above (2.1.5). 
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The pMX-pie vector fragment and the NF-IL6 insert were ligated as described in 2.4.2.C. Then 2µl 
of ligation were transformed as described in 2.4.2.D. Positive clones were selected after a BamHI, 
XhoI control cut which should result in a ~1050bp fragment and then sequenced by Sequiserve. A 
clone that showed no mismatch with the genomic sequence of NF-IL6 was amplified with Qiagen 
Maxiprep (2.1.2). 
 
2.4.6. Cloning of a retroviral NF-κB p65 expression construct 
The sequence of the full length NF-κB p65 protein was cloned as a 5’ - BamHI and 3’ - XhoI cut 
~1650bp fragment into the vector pMX-pie, resulting in the plasmid pMX-pie- NF-κB p65. The 
DNA fragment for NF-κB p65 was amplified from 1ng of the plasmid RcCMV-p65 which already 
contained the sequence of wild-type NF-κB p65. This plasmid was kindly provided by R. deMartin 
(University of Medicine, Vienna). 
The PCR Primers MW1467 5’- GACTGGATCCCTGGGCACCATGGACGAACTGTTCCCCCTC 
-3’ containing an artificial BamHI adapter (underlined) and MW1468 5’- 
CTGACTCGAGTTAGGAGCTGATCTGACTCAGC-3’ containing an artificial XhoI adapter 
(underlined) were used for PCR. The Herculase Hotstart polymerase (Stratagene) and its 
corresponding 10x buffer were used for PCR. The following parameters were used for 
amplification: 1min incubation at 95°C followed by 35 cycles of incubation for 40sec at 95°C, 
40sec at 62°C and 3.30min at 72°C. The resulting PCR products was loaded onto a 1% agarose gel, 
containing ethidium bromide and the gel was run for 45 min at 80V (2.1.4). Under UV-light the 
desired band was cut out with a clean scalpel and the DNA was further isolated using the QIAquick 
gel extraction Kit protocol (2.1.5). The isolated PCR fragment, which was eluted in 10µl nuclease 
free H2O (2.1.5) and the vector pMX-pie were cut with BamHI and XhoI in 1xBamHI buffer, 
supplemented with 1xBSA and incubated for 1h at 37°C.  
The digested PCR fragment and the restricted vector were both loaded onto a 1% agarose gel, after 
gel run the digested fragments were isolated as described above (2.1.5). 
The pMX-pie vector fragment and the NF-κB p65 insert were ligated as described in 2.4.2.C. Then 
2µl of ligation were transformed as described in 2.4.2.D. Positive clones were selected after a 
BamHI, XhoI control cut which should result in a ~1650bp fragment and then sequenced by 
Sequiserve. A clone that showed no mismatch with the genomic sequence of NF-κB p65 was 
amplified with Qiagen Maxiprep (2.1.2). 
 
2.4.7. Cloning of the lentiviral PU.1 gene silencing construct GIPZ-sh-PU.1 
The lentiviral vector constructs GIPZ-sh-PU.1 and GIPZ-sh-Control were kindly provided by Prof. 
Dr. H. Strobl (University of Medicine, Vienna). The lentiviral vectors encoding shRNA mir for the 
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PU.1 gene or a non silencing shRNA mir Control were purchased from Open Biosystems. The two 
lentiviral packaging vectors pPAX2 and pMD2G were also kindly provided by Prof. Dr. H. Strobl. 
 
2.5 ELISA for human Interleukin-6  
First all used wells of a Maxisorp Immuno plate (Nalgene Nunc International) were coated with 
50µl 1x PBS containing anti-human Interleukin-6 antibody (R+D MAB206; 500µg/ml in PBS + 
0,1% FCS) at a final concentration of 2µg/ml at 4°C over night. Then the plate was washed four 
times with wash buffer (PBS def. pH 7,5 + 0,05% Tween 20). Recombinant human Interleukin-6 
(R+D, 20ng/µl, in PBS + 0,1% FCS) was used as standard with 2ng/ml start concentration and then 
diluted 1:2 in dilution buffer (PBS + 0,05% Tween 20). All samples were also diluted in dilution 
buffer in a final volume of 50µl/well and incubated for 2h at RT. Then the plate was washed again 
four times with wash buffer. Detection anti body a-human Interleukin-6-biotin conjugate (R+D 
BAF206, 50µg/ml in PBS + 0,1% FCS) was added at a final concentration of 40ng/ml in 50µl 
dilution buffer per well and incubated for 2h at RT. The plate was washed again four times with 
wash buffer before the enzyme-conjugate strepdavidin peroxidase (R+D), diluted 1:200 in 50µl 
dilution buffer, was added to each well and incubated for 30 min at RT. Meanwhile fresh substrate 
was prepared by mixing one volume of Solution A with one volume of Solution B supplied in the 
Substrate Reagent Pack Kit (R+D). The plate was washed four times in wash buffer. 50µl of fresh 
substrate solution were added to each well and incubated for 30 min at RT. The reaction was 
stopped by adding 25µl 15% H2SO4 to each well. Then the plate was measured in a Spectramax 190 
luminometer (Molecular Devices) at 450nm (reference 570nm). Then raw data was analyzed and 
graphs were made using the Excel program. 
 
2.6 Western blot analysis  
2.6.1 Preparation of whole cell lysates 
For the generation of whole cell lysates 2 x 105 Monomac1 cells were harvested by centrifugation 
for 7 min at 1300rpm, medium was removed and cells were resuspended in 80 µl 1 x PBS 
containing 1x protease inhibitor cocktail solution (Roche) and 1x phosphatase inhibitor cocktail 
solution (Roche). Then 80 µl of sample reducing buffer (Santa Cruz Biotechnology), which had 
been prewarmed to RT first, were added to the cells and mixed by pipetting up and down several 
times. Lysate samples were then heated on a heating block  for 5 min at 95°C and cooled down to 
RT before they were loaded onto a Tris-Glycine gel (2.6.2). 
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2.6.2 Tris-Glycine gel electrophoresis, blotting to nitrocellulose membrane and blocking 
Before usage of ready-made 4-20% SDS Tris-Glycine gels (Invitrogen) each slot was washed with 
1 x Tris-Glycine SDS running buffer (Invitrogen) before inserting the gel into the Xcell Sure Look 
device (Invitrogen), which was then filled with 1 x Tris-Glycine SDS running buffer. About 50 µg 
of protein per sample were loaded into each slot, and 8 µl of SeeBluePlus2 prestained standard 
(Invitrogen) was used as a size marker. All gels were run using the PowerEase500 Electrophoresis 
Supply Unit (Invitrogen) for 1.5 h at 125V. 
After the gel electrophoresis run had completed, the Tris-Glycine gel was opened by careful 
breakage and transferred to a Xcell II™ Blot Module (Invitrogen). Starting from the cathode core 
side, sandwich blotting was used: two blotting pads were inserted first, followed by a filter paper 
onto which the Tris-Glycine gel was carefully placed. A nitrocellulose membrane (Invitrogen) with 
a pore size of 0.2µm was laid slowly onto the gel, avoiding the forming of air bubbles between 
nitrocellulose membrane and gel. The nitrocellulose membrane was then covered with one filter 
paper and two blotting pads and the sandwich was closed with the anode side. All blots were run 
using the PowerEase500 Electrophoresis Supply Unit (Invitrogen) for 1.5 h at 25V. 
After the blotting process, the nitrocellulose membrane was carefully transferred to a plastic 
container, with the protein side on top. Then the nitrocellulose membrane was blocked in blocking 
buffer (1 x TBS containing 0.1% Tween 20 and 2.5% non-fat milk (Fluka Biochemica)) and 
incubated at RT for at least one hour or over night at 4°C. 
 
2.6.3 Western Blot of the aryl hydrocarbon receptor 
After blocking, the nitrocellulose membrane was washed two times with wash buffer (1 x TBS 
containing 0.1% Tween 20) for 10 minutes each washing step, at RT. The membrane was then 
incubated with a 1:500 dilution of the first antibody polyclonal goat anti-human Ah Receptor IgG 
(Santa Cruz Biotechnology, N-19) in blocking buffer for 2 hours at RT. Then the membrane was 
washed with wash buffer four times, 10 min each wash step, at RT. Next the membrane was 
incubated with a 1:5000 dilution of the second antibody donkey anti-goat IgG (Santa Cruz 
Biotechnology) coupled to horse radish peroxidase (HRP) for 2 h at RT. The membrane was 
washed again four times with wash buffer at RT before subtrate for HRP was added (2.6.9). 
 
2.6.4 Western Blot of STAT5 and STAT6 
The nitrocellulose membrane was blocked in blocking buffer (2.6.2) over night at 4°C. On the next 
day the membrane was washed two times with wash buffer (2.6.3) for 10 minutes each washing 
step, at RT. Then the membrane was incubated with a 1:1.000 dilution of the first antibody mouse 
anti-human STAT5 or mouse anti-human phospho STAT5 in blocking buffer for 2 hours at RT.  
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The same dilution was used for mouse anti-human STAT6 or mouse anti-human phospho-STAT5 
antibodies. All STAT antibodies were provided in the STAT activation sampler kit (BD 
Biosciences, #612477). Then the membrane was washed with wash buffer four times, 10 min each 
wash step, at RT. Next the membrane was incubated with a 1:10.000 dilution of the second 
antibody donkey anti-mouse IgG (Santa Cruz Biotechnology) coupled to horse radish peroxidase 
(HRP) for 2 h at RT. The membrane was washed again four times with wash buffer at RT before 
subtrate for HRP was added (2.6.9). 
 
2.6.5 Western Blot of the p44/p42 MAP kinases 
After blocking the nitrocellulose membrane for one hour at RT, the membrane was incubated with a 
1:1000 dilution of the first antibody polyclonal rabbit anti-human p44/p42 MAP kinase (Cell 
Signaling Technology, #9102) or polyclonal rabbit anti-human phospho p44/p42 MAP kinase (Cell 
Signaling Technology, #9101) in blocking buffer over night at 4°C. On the next day the membrane 
was washed with wash buffer (2.6.3) four times, 10 min each wash step, at RT. Next the membrane 
was incubated with a 1:15.000 dilution of the second antibody goat anti-rabbit IgG (BioRad) 
coupled to horse radish peroxidase (HRP) for 2 h at RT. The membrane was washed again four 
times with wash buffer at RT, followed by incubation of the membrane with substrate for HRP 
(2.6.9). 
 
2.6.6 Western Blot of NF-IL6 
The nitrocellulose membrane was blocked in blocking buffer (2.6.2) over night at 4°C. On the next 
day the membrane was washed two times with wash buffer (2.6.3) for 10 minutes each washing 
step, at RT. Then the membrane was incubated with a 1:1.000 dilution of the first antibody mouse 
anti-human C/EBP β (Santa Cruz Biotechnology, SC-7962) in blocking buffer for 2 hours at RT. 
Then the membrane was washed with wash buffer four times, 10 min each wash step, at RT. Next 
the membrane was incubated with a 1:10.000 dilution of the second antibody sheep anti-mouse IgG 
(Amersham) coupled to horse radish peroxidase (HRP) for 2 h at RT. The membrane was washed 
again four times with wash buffer at RT before substrate for HRP was added (2.6.9). 
 
2.6.7 Western Blot of NF-κB p65 
After blocking the nitrocellulose membrane for one hour at RT, the membrane was incubated with a 
1:1000 dilution of the first antibody polyclonal rabbit anti-human NF-κB p65 (Upstate Cell 
Signaling, #06-418) in blocking buffer over night at 4°C. On the next day the membrane was 
washed with wash buffer (2.6.3) four times, 10 min each wash step, at RT. Next the membrane was 
incubated with a 1:15.000 dilution of the second antibody goat anti-rabbit IgG (BioRad) coupled to 
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horse radish peroxidase (HRP) for 2 h at RT. The membrane was washed again four times with 
wash buffer at RT, followed by incubation of the membrane with substrate for HRP (2.6.9). 
 
2.6.8 Western Blot of PU.1 
After blocking the nitrocellulose membrane for one hour at RT, the membrane was incubated with a 
1:1000 dilution of the first antibody polyclonal rabbit anti-human PU.1 (Santa Cruz Biotechnology, 
SC-352) in blocking buffer over night at 4°C. On the next day the membrane was washed with 
wash buffer (2.6.3) four times, 10 min each wash step, at RT. Next the membrane was incubated 
with a 1:15.000 dilution of the second antibody goat anti-rabbit IgG (BioRad) coupled to horse 
radish peroxidase (HRP) for 2 h at RT. The membrane was washed again four times with wash 
buffer at RT, followed by incubation of the membrane with substrate for HRP (2.6.9). 
 
2.6.9 Substrate for HRP and western blot developing 
The substrate for HRP was prepared by mixing one volume of SuperSignal West Pico Stable 
Peroxide solution with one volume of SuperSignal West Pico Luminol/Enhancer Solution 
supplied in the SuperSignal™ kit (Pierce). 
After washing the membrane was incubated with fresh-prepared substrate mix for 5 min at RT. 
Then substrate was removed and the membrane was sealed into a transparent plastic bag and 
transferred to a BioMax cassette (Kodak) where it was exposed to a high performance 
chemiluminescence film (GE Healthcare), followed by the development of the film in a Curix60 
film developer (Agfa). 
 
2.7 Cells, cell culture conditions and inducers  
2.7.1 Thawing and growing of cells from liquid nitrogen 
The vials containing the frozen cells were thawed by RT and were immediately poured into 
prewarmed full medium. The cells were washed once, by centrifugation for 7 min at 1300rpm, 
removing the supernatant and resuspending them in prewarmed full medium. Cells were transferred 
in a cell culture flask and grown at 37°C with 5% CO2. Cells were split every 3 to 4 days at a ratio 
between 1:5 and 1:10 (depending on growth speed of each cell line) with fresh medium to a final 
volume of 20ml.  
 
2.7.2 Freezing of cells for liquid nitrogen storage 
Cells were counted using a Neubauer type hematocytometer and were harvested by centrifugation for 7 
min at 1300rpm. The cell pellet was resuspended with the needed amount of ice-cold freezing medium 
(90% Fetal Bovine Serum (GIBCO) and 10% DMSO) to get 1x107 cells/ml. The cells were aliquoted 
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into 1ml Nunc Cryo tubes (Nalgene Nunc International), capped and left in a Nalgene™ Cryo 1°C 
Freezing Container (Nalgene) on -80°C for about one week. Then the cells were inserted into the 
liquid nitrogen tank for long term storage. 
 
2.7.3 Monomac1 cells 
The human monocytic cell line Monomac1 growed in suspension, with a round shape similar to that 
of fresh human monocytes. Cells were split every 3 to 4 days with fresh medium at a ratio of about 
1:10. MM1 were kept in RPMI1640 supplemented with 10% heat-inactivated fetal bovine serum 
(GIBCO), 2mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1.5g/l sodium bicarbonate, 
4.5g/l glucose, 10mM HEPES, 1mM sodium pyruvate and 1% non essential amino acids (GIBCO) at 
37°C supplemented with 5% CO2. 
 
2.7.4 PhoenixA cells 
The PhoenixA cell line is derived from primary human embryonal kidney and grows adherent on 
the cell culture flask. PhoenixA cells were cultured in DMEM medium supplemented with 10% heat-
inactivated Fetal Bovine Serum (GIBCO), 2mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin and kept in culture at 37°C supplemented with 5% CO2. When split, the complete 
medium was carefully decanted from the cell culture flask and the adherent cells were shortly 
incubated with 4ml Trypsin/EDTA solution (Invitrogen). The Trypsin/EDTA solution was poured of 
completely and the cells were incubated for 5 min at 37°C. Upon gently shaking of the cell culture 
flask, the cells would get off the surface and were resuspended in 10ml of fresh medium. Then the cells 
were split at a ratio of 1:10 with fresh medium. 
 
2.7.5 PhoenixGP cells 
The PhoenixGP cell line, also known as HEK 293T cell line is derived from primary human 
embryonal kidney and grows adherent on the cell culture flask. PhoenixGP cells were cultured in 
DMEM medium supplemented with 10% heat-inactivated Fetal Bovine Serum (GIBCO), 2mM 
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and kept at 37°C supplemented with 5% 
CO2.  When split, the complete medium was carefully decanted from the cell culture flask and the 
adherent cells were detached by trypsination (2.7.4) and split at a ratio of 1:10 with fresh medium. 
 
2.7.6 Cell inducers, compounds and inhibitors 
If not available as stock in house, recombinant human cytokines were purchased from RnD 
Systems. Human recombinant GM-GSF stock was available in house and used at a final 
concentration of 50ng/ml. Human recombinant IL-4 was used at a final concentration of 40ng/ml. 
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Human recombinant TNF-α and IFN-γ were used at a final concentration of 100U/ml. Human 
recombinant IL-1β and IL-3 were used at a final concentration of 10ng/ml. Lipopolysaccharide 
(LPS) was purchased from Calbiochem and used at a final concentration of 100ng/ml. 
Saccharomyces cerevisiae zymosan A was purchased from Sigma-Aldrich and was used at a final 
concentration of 5µg/ml. Phorbol 12-myristate 13-acetate (PMA) was also purchased from Sigma-
Aldrich and used at a final concentration of 20 nM. A mouse anti-human CD40 (α-CD40)-IgG 
antibody was available in house and was used together with a cross linking goat anti-mouse IgG 
antibody at a final concentration of 1µg/ml each.  
VAF347 ([4-(3-chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine) and VAG005 (4-
(2-chloro-pyridin-4-yl)-2-(4-chloro-3-trifluoromethyl-phenoxy)-pyrimidine) were synthesized at 
Novartis. TCDD, with a purity of >99%, was purchased from Crescent Chemical Company. 
Omeprazole was available in house. 
The JAK-3 inhibitor CP-690,550 was available in house. The NF-κB inhibitor 
pyrrolidinedithiocarbamate was purchased from Sigma-Aldrich. An “NF-κB activation inhibitor” 
(6-Amino-4-(4-phenoxyphenylethylamino)quinazoline), the MAP kinase inhibitor PD98059 as well 
as the PKC inhibitors Calphostin C, BisindolylmalmeideI, Ro-32-0432 and Goe6976 were obtained 
from Calbiochem. 
 
2.8 Induction of Monomac1 cells 
2.8.1 Induction of Monomac1 cells for RT-PCR and IL-6 ELISA 
1x106 cells/sample (counted with a Neubauer hematocytometer) of Monomac1 cells (2.7.3) were 
harvested, resuspended in 3ml full medium (2.7.3) and seeded in a 6 well plate (Costar). VAF347 
was always added to cells first, then cytokines were added (2.7.6). Samples containing inhibitors 
(2.7.6) were pre-incubated with the respective inhibitor for 1h at 37°C supplemented with 5% CO2, 
before VAF347 and/or cytokines (2.7.6) were added. Following induction cells were incubated for 
24h at 37°C with 5% CO2, if not stated otherwise.  
After 24h incubation cells were transferred into 15ml Tubes (Falcon) and harvested by 
centrifugation at 1300rpm for 7 min. Medium was completely removed, with aliquots of each 
supernatant being stored at –80°C for the detection of human IL-6 by ELISA (2.5). Each sample 
was lysed in 400µl of Lysis Buffer, containing 3.5µl β-Mercaptoethanol. All reagents for RNA 
isolation were provided in the Absolutely RNA RT-PCR Miniprep Kit (Stratagene). All further steps 
regarding the total RNA isolation were done as described in 2.2.1. Following RNA isolation,  
cDNA generation was done according to the description in 2.2.2 . Gene expression was analyzed by 
input of cDNA into quantitative RT-PCR (2.3). 
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2.8.2 Induction of Monomac1 cells for analysis of intracellular signaling events 
Monomac1 cells were counted with a Neubauer hematocytometer and harvested by centrifugation at 
1.300rpm for 7min. 3x105 cells/sample were resuspended in 1ml full medium (2.7.3) and seeded into 
a 24 well plate (Costar). Samples containing inhibitors (2.7.6) were pre-incubated with the 
respective inhibitor for 1h at 37°C supplemented with 5% CO2 before VAF347 or cytokines (2.7.6) 
were added. Various time points after stimulation, cells were harvested by centrifugation at 
1.300rpm for 2min and whole cell lysates were prepared immediately (2.6.1). Whole cell lysates 
were then used for the detection of multiple phosphorylated or unphosphorylated proteins by 
western blotting (2.6.2). 
 
2.9 Transient transfection of MM1 using the Amaxa electroporation device  
2x106 of Monomac1 cells (2.7.3) per sample were harvested by centrifugation for 7min at 1.300 
rpm. Pelleted cells were washed once with 20 ml of cold 1xPBS and centrifuged for 7min at 
1.300rpm. PBS was decanted completely and cells were carefully resuspended in 100µl transfection 
solution V. 2µg plasmid DNA (eGFP expression vector or pGL3-Interleukin-6 promoter) were 
added to 100µl of cell suspension. Then the cell solution was pipetted into a 1ml Amaxa certified 
transfection cuvette, and the cuvette was shaken by hand shortly. 
The cuvette was then inserted into the cuvette holder of the Amaxa Nucleofetor device™ and the 
electroporation program V-01 was selected and started. To avoid damage to the cells, samples were 
removed immediately after the program had finished and 900µl of prewarmed full medium (2.7.3) 
were added directly to the cells in the cuvette. Then the cell suspension was transferred into 3ml of 
prewarmed medium in six well plates (Costar) and incubated for 24h with or without PMA (20nM), 
human IL-4 (40ng/ml) + GM-CSF (50ng/ml) in the presence or absence of VAF347 (50nM) or 
VAG005 (50nM) respectively, at 37°C supplemented with 5%CO2 before luciferase activity was 
measured (2.9.2). GFP expression was checked in a confocal fluorescence microscope (Leica).  
 
2.9.1 Luciferase activity measurement 
24h after cytokine stimulation, each sample was transferred to a 15ml centrifugation tube (Costar) 
and cells were harvested by centrifugation at 1.300 rpm for 7min. 
The supernatants were removed by pipetting and the cells were lysed in 90µl of 2x Passive Lysis 
buffer (Promega). 2x 40µl of each lysate were pipetted into a 96 well plate (Dynex Technologies) 
resulting in duplicates for each well. The samples were measured in a luminometer (Luminoskan, 
Labsystems) with the following parameters: 50µl of luciferase assay substrate were injected into 
each well and after a lag-time of 1sec the light quantity was measured for 4sec. The raw data was 
analyzed and graphs were made using the Excel program. 
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2.10 Viral infection of Monomac1 cells  
2.10.1 Transfection of packaging cell lines with retroviral constructs 
On the day before transfection 1.7x106 PhoenixA (2.7.4) or Phoenix GP (2.7.5) cells were seeded in 
4ml of fresh medium (2.7.4) without antibiotics, per 25 cm² cell culture flask (Costar). The 
packacking cell line was transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen). 
First 15µl of Lipofectamine2000 reagent were diluted gently in 500µl Opti-MEM® I medium 
(Invitrogen) and incubated for 5 min at RT. Meanwhile 9µg of plasmid DNA (pMX-pie vector, 
pMX-pie-AhR515, LMP-shAhR, LMP-shControl, pMX-pie-NF-IL6, pMX-pie-NF-κB p65) were 
diluted in 500µl Opti-MEM® I reduced serum medium and mixed gently. In the case of PhoenixGP 
transfection, 5µg of the packaging vector GalV were added to each transfection sample. 
After 5 min incubation, DNA and Lipofectamine2000 (Invitrogen) solutions were combined, mixed 
gently and incubated for 20 min at RT. The complete mixture was then added drop-wise onto the 
cells which were then further incubated for 24h at 37°C supplemented with 5%CO2. On the next 
day the medium was removed completely by pipetting and replaced with 4 ml of fresh prewarmed 
medium (2.7.4), containing 100 U/ml penicillin, 100 µg/ml streptomycin. Then the cells were further 
incubated for 24 h at 37°C supplemented with 5%CO2. 
 
2.10.2 Transfection of a packaging cell line with lentiviral constructs 
On the day before transfection 1.7x106 Phoenix GP cells were seeded in 4ml of fresh medium 
(2.7.5) without antibiotics, per 25 cm² cell culture flask (Costar). The packacking cell line was 
transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen). First 32µl of 
Lipofectamine2000 reagent were diluted gently in 500µl Opti-MEM® I medium (Invitrogen) and 
incubated for 5 min at RT. Meanwhile 10µg of sh-RNA construct (GIPZ-sh-Control or GIPZ-sh-
PU.1), 7µg of the packaging vector pPAX2 as well as 3µg of the second packaging vector pMD2G 
were diluted in 500µl Opti-MEM® I reduced serum medium and mixed gently.  
After 5 min incubation, DNA and Lipofectamine2000 (Invitrogen) solutions were combined, mixed 
gently and incubated for 20 min at RT. The complete mixture was then added drop-wise onto the 
PhoenixGP cells which were then further incubated for 24 h at 37°C supplemented with 5%CO2. 
On the next day, the medium was removed completely by pipetting and replaced with 4 ml of fresh 
prewarmed medium (2.7.5), containing 100 U/ml penicillin, 100 µg/ml streptomycin. Then cells 
were further incubated for 24 h at 37°C supplemented with 5%CO2. 
 
2.10.3 Retroviral infection of Momomac1 cells 
For the successful retroviral infection and deliverage of virus information into the mammalian cell, 
cells needed to be in a dividing phase. Therefore Momomac1 cells were split at a ratio of 1:10 two 
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days before transduction to allow cells to grow. On the day of infection Monomac1 cells were 
counted, harvested by centrifugation for 7min at 1.300 rpm and resuspended at a concentration of 5 
x 105 cells per 100µl in fresh full medium (2.7.3). 
 
The virus containing supernatant of PhoenixA or PhoenixGP cells was collected by pipetting and 
filtered through a 0.45 µm filter (Millipore). After filtration polybrene (Sigma-Aldrich) was added 
to the supernatant to give a final concentration of 1µg/ml. To control Lipofectamine 2000 
transfection efficiency, GFP expression in PhoenixA or respectively PhoenixGP cells was checked 
in a confocal fluorescence microscope (Leica). 
Infection of Monomac1 cells was achieved by adding 2 ml of viral supernatant to 5 x 105 
Monomac1 cells, seeded in 24-well plates (Costar), followed by centrifugation at 310 x g for 3 h at 
RT. Immediately after centrifugation cells were incubated again at 37°C supplemented with 
5%CO2. After a 24 h incubation step cells were harvested by centrifugation for 7min at 1.300 rpm, 
the medium was removed and replaced with fresh Monomac1 medium (2.7.3) and the cells were 
allowed to grow for 2-3 days. Then cells expressing high levels of GFP were sorted using a 
FACSVantage SE machine (Becton Dickinson). Sorted GFP positive cells were cultured in medium 
(2.7.3) supplemented with 1 µg/ml puromycin (Sigma-Aldrich) at 37°C supplemented with 5%CO2. 
 
2.10.4 Lentiviral infection of Momomac1 cells 
Lentiviral infection of MM1 cells was achieved by using the same protocol applied for retroviral 
infection of MM1 cells (2.10.3). 
 
2.11 Chromatin Immunoprecipitation  
2.11.1 Induction of Monomac1 cells 
If not stated otherwise, all reagents necessary for Chromatin Immunoprecipitation (ChIP) were 
supplied in the ChIP Kit from Millipore. First 1x106 cells/ ChIP sample (counted with a Neubauer 
hematocytometer) of Monomac1 were harvested, resuspended in 3ml full medium (2.7.3) and 
seeded into a 6 well plate (Costar). Monomac1 cells were left untreated or stimulated with IL-4 
(with a final concentration of 40ng/ml) and GM-CSF (with a final concentration of 50ng/ml) in the 
absence or presence of 50 nM VAF347 and incubated for 24h at 37°C, supplemented with 5%CO2.  
 
2.11.2 Crosslinking and lysis 
To cross link histones to DNA, formaldehyde (Sigma-Aldrich) was added directly to Monomac1 cells 
to a final concentration of 0.7% and incubated for 10 min at 37°C. Then Monomac1 cells were 
harvested by centrifugation for 6min at 1.300 rpm. Pelleted cells were washed twice with ice cold 
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1xPBS containing 1x protease inhibitor cocktail (Roche Diagnostics). PBS was decanted 
completely and 1x106 cells were lysed in 200µl SDS Lysis Buffer, which had been pre-warmed to 
RT first and contained 1x protease inhibitor cocktail. Lysates were left on ice for 10 min before 
protocol was continued with DNA fragmentation (2.11.3) 
 
2.11.3 Random DNA fragmentation 
All cross linked ChIP samples (2.11.2) were sonicated with the Bioruptor machine (Diagenode). 
DNA was sheared to a length between 400-1000 bp in 10 sonication cycles using the Bioruptor on 
power setting “High” (200 W). One sonication cycle of 1 min included 30 sec sonication and 30 sec 
pause. Lysate samples were always kept on ice or in ice cold water during sonication. 
After sonication ChIP samples were centrifuged for 10 min at 13.000 rpm at 4°C, then supernatants 
(containing sheared DNA) were transferred into new 2ml Eppendorf microcentrifuge tube. 
 
2.11.4 Immunoprecipitation and washing 
Before protocol was continued 50µl of sonicated DNA lysate of each sample were taken away and 
labelled with Input. Input samples were stored at –20°C until the elution step (2.11.5). 
For each immunoprecipitation ChIP sample sonicated DNA of 1x106 cells (2.11.3), contained in 200µl 
lysate, was usded. Each ChIP sample was diluted 10 fold in ChIP dilution buffer, containing 1x 
protease inhibitor cocktail, meaning that 200µl lysate were filled up with 1800µl ChIP dilution 
buffer in a 2 ml Eppendorf microcentrifuge tube. To reduce non-specific background, all samples were 
pre-cleared with 60µl of Salmon Sperm DNA/Protein A Agarose-50% Slurry for 1 h at 4°C with 
rotation. Agarose was pelleted by centrifugation for 1min at 1.800 rpm, at 4°C. Pre-cleared 
supernatants were transferred into fresh 2ml Eppendorf microcentrifuge tube, before the 
immunoprecipitating antibodies were added. To precipitate the transcription factor NF-IL6 10µg of the 
polyclonal rabbit anti-human C/EBP  antibody SC-150 X (Santa Cruz Biotechnology) were added. 
As negative controls samples containing 10µg of normal rabbit IgG SC-2027 (Santa Cruz 
Biotechnology) or samples containing no antibody were inculded. After antibodies were added, 
samples were incubated over night at 4°C with rotation. On the next day 60µl of Salmon Sperm 
DNA/Protein A Agarose-50% Slurry were added to each sample for 4 h at 4°C with rotation to collect 
antibody/histone complex. Agarose was pelleted by centrifugation for 1min at 1.800 rpm, at 4°C and 
supernatant containing unbound non-specific DNA was removed carefully by pipetting. Then samples 
were washed for 5 min on a rotation platform with 1 ml of each of the wash buffers listed in the order 
as given bellow:  
a) Low Salt Immune Complex Wash Buffer, one wash at 4°C 
b) High Salt Immune Complex Wash Buffer, one wash at 4°C 
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c) LiCl Immune Complex Wash Buffer, one wash at 4°C 
d) 1 x TE, two washes at RT 
Protocol was continued with elution of the histone complex from the antibody (2.11.5). 
 
2.11.5 Elution and Proteinase K digest 
Fresh elution buffer containing 1%SDS and 0.1M NaHCO3 was prepared. The histone complex was 
then eluted from the antibody ba adding 250µl of fresh elution buffer, samples were vortexed briefly 
and incubated for 15 min on rotation at RT. Agarose was pelleted by centrifugation for 1min at 1.800 
rpm, at RT and supernatant fraction (eluate) was transferred into a fresh 1.5 ml Eppendorf 
microcentrifuge tube by pipetting. The elution step was repeated one more time and both eluates were 
combined (~500µl eluate). At this point the protocol was also continued for the Input samples: Input 
samples were thawed and filled up with elution buffer to a final volume of 500µl. Then 50µl of 5M 
NaCl were added to the eluates and all samples were incubated at 65°C over night to reverse 
DNA/Histone crosslinks. On the next day 10µl of 0.5M EDTA, 20µl of 1M Tris-HCl pH 6.5 and 1µl 
of 600 mAu/ml Protease K (Novagen) were added to each sample and incubated for 1 h at 45°C.  
 
2.11.6 Phenol/chloroform extraction and PCR 
After Proteinase K digest (2.11.5) DNA was recovered by phenol/chloroform extraction. Therefore 
500µl of phenol/chloroform/isoamylalcohol 25:24:1 (Sigma-Aldrich) were added to each sample, 
followed by 5 sec vortexing. Samples were centrifuged for 2 min at 13.000 rpm, before the top phase 
was carefully transferred into a fresh 1.5 ml Eppendorf microcentrifuge tube by pipetting. Before 
precipitation 20µg of glycogen (Calbiochem) were added as an inert carrier to help visualize the DNA 
pellet. To precipitate DNA 1ml of 96% ethanol was added and samples were left on –20°C over night. 
On the next day DNA was pelleted by centrifugation of the samples for 25 min at 13.000 rpm, at 4°C. 
The supernatant was removed carefully and DNA pellets were washed with 500µl of 70% ethanol, 
followed by centrifugation of the samples for 10 min at 13.000 rpm, at 4°C. the 70% ethanol was 
removed carefully and the DNA pellets were allowed to air dry before pellets were resuspended in 
50µl of nuclease free H2O. 
For PCR the conditions already described for RT-PCR were used (2.3). For the detection of the 
C/EBP- (NF-IL6) binding site in the human IL-6 promoter by RT-PCR, following 
oligonucleotides were used: 
MW1482: upstream 5´- AATGACGACCTAAGCTGCAC-3´ and MW1483: downstream 5´- 
CTTTGTTGGAGGGTGAGGGT-3´. 
For each ChIP sample 5µl of recovered DNA were used for RT-PCR, for Input samples only 1µl of 
recovered DNA were used. After RT-PCR 18µl of each PCR reaction were mixed with 2µl of 
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10xBlue Juice Gel loading buffer (Invitrogen) and loaded onto a 1.3% agarose gel, which was run 
as described above (2.1.4). 
 
2.12 Statistical analysis  
The Student’s t-test was used to analyse data for significant differences. P-values less than 0.05 
were regarded as significant. 
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3. RESULTS  
 
3.1 IL-4 + GM-CSF induce Interleukin-6 expression in human Monomac1 cells 
Fresh human Monomac1 (MM1) cells (2.7.3) were seeded into 6 well plates at a density of 1x106 
cells per well and incubated for 24 hours (or different time points if stated otherwise) in the 
presence or absence of the cytokines IL-4, GM-CSF (2.7.6) or IL-4 and GM-CSF in combination 
(2.8.1). After 24 hours RNA was isolated with the Absolutely RNA Kit (2.2.1) and used to generate 
cDNA according to the protocol of the iScript cDNA synthesis Kit (2.2.3). These cDNA templates 
were then further analyzed by RT-PCR (2.3) for the expression levels of Interleukin-6 and 
elongation Factor-1 (eF-1) as a house keeping control gene (2.3). For the calculation of the 
expression values for this and all following RT-PCR experiments, the average Ct values of the gene 
of interest were normalized to the average of the Ct values of the eF-1 gene.  
 
Figure 3.1.1: GM-CSF induces IL-6 production in Monomac1 cells. IL-4 induces only little IL-6 
synthesis but enhances IL-6 expression in combination with GM-CSF. RT-PCR for IL-6 mRNA 24h 
after cytokine stimulation is shown. IL-6 expression was normalized to eF-1 expression. The error 
bars indicate standard deviation. 
 
The RT-PCR data showed that IL-6 expression was induced 24 hours after stimulation with  
GM-CSF in Monomac1 cells (Figure 3.1.1). IL-4 alone had only very little effect on IL-6 
expression on its own but acted in a synergistic way with GM-CSF on Monomac1 cells.  
To determine the time course of interleukin-6 induction, Monomac1 cells were cultured for up to  
48 hours with IL-4 + GM-CSF before IL-6 mRNA expression was determined by RT-PCR as 
described above. As shown in Figure 3.1.2 IL-6 expression levels increased with time, reaching a 
maximum at 48 hours after cytokine induction. After three days of cytokine stimulation the 
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interleukin-6 response measured at the mRNA level was already down-regulated to the starting 
level (data not shown). 
 
 
Figure 3.1.2: Il-4 + GM-CSF induce IL-6 production in Monomac1 cells. IL-6 mRNA levels were 
measured by RT-PCR 4h, 24h and 48h after cytokine stimulation. IL-6 expression was normalized to 
eF-1 expression. 
 
3.2 VAF347 inhibits IL-4 + GM-CSF induced IL-6 production in Monomac1 cells 
To answer the question whether the inhibitory effect of VAF347 on IL-6 production by human 
monocyte-derived DCs (63) was restricted to primary cells or could also be seen in a monocytic cell 
line, we examined the biological activity of VAF347 on Monomac1 cells.  
MM1 cells (2.7.3) were stimulated with IL-4 + GM-CSF in the presence or absence of VAF347 
(2.7.6) for 24 hours, before IL-6 mRNA expression was analyzed by RT-PCR (2.3).  
As shown in Figure 3.2.1, stimulation of Monomac1 cells with IL-4 + GM-CSF lead to induction 
of IL-6 expression. In MM1 cells that had been stimulated with IL-4 + GM-CSF in the presence of 
VAF347, IL-6 expression was inhibited in a dose-dependent fashion. Usually, the IL-4 + GM-CSF 
induced IL-6 mRNA expression was inhibited by >4-fold at a concentration of 50nM VAF347.  
The half-maximal inhibitory concentration (IC50) of VAF347 in Monomac1 cells was 
approximately 5nM, a concentration which was very similar to that calculated for the blockade of 
interleukin-6 production in monocyte-derived DCs (63). VAF347 on its own did not induce IL-6 
expression in MM1 cells (Figure 3.2.1). 
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Figure 3.2.1: VAF347 inhibits IL-4 + GM-CSF induced IL-6 production in Monomac1 in a dose-
dependent fashion. IL-6 mRNA expression was analyzed by RT-PCR 24h after cytokine stimulation. 
IL-6 expression was normalized to eF-1 expression.  
 
The inhibitory effect of VAF347 still persisted in cells stimulated for 48 hours (Figure 3.2.2).  
 
Figure 3.2.2: VAF347 inhibits IL-4 + GM-CSF induced IL-6 production in Monomac1. IL-6 mRNA 
expression was analyzed by RT-PCR 48h after cytokine stimulation and normalized to eF-1 
expression. 
 
To examine if the inhibitory effect of VAF347 on IL-6 mRNA expression could also be seen at the 
protein level, IL-6 protein was measured in cell supernatants by ELISA (2.5).  
 
 
nil            0           50           10            2            0.4           50      VAF347 (nM) 
IL-4/GM-CSF
0 
10 
20 
30 
40 
50 
IL
-6
 m
R
N
A
 
no
rm
al
iz
ed
 e
xp
re
ss
io
n 
(2
4h
) 
 
0 
10 
20 
30 
40 
50 
60 
IL-4/GM-CSF 
nil            0             50           10             2            0.4           50       VAF347 (nM) 
IL
-6
 m
R
N
A
 
no
rm
al
iz
ed
 e
xp
re
ss
io
n 
(4
8h
) 
Results 
 51
The ELISA data shown in Figure 3.2.3 demonstrated that IL-6 protein was detectable in 
supernatants of MM1 cells at a concentration of 250pg/ml 24 hours after stimulation with IL-4 + 
GM-CSF. VAF347 inhibited the production of IL-6 protein in a concentration dependent manner. 
Usually, the factor of inhibition of IL-6 protein production by 50nM VAF347 (which was ten times 
higher then the calculated IC50) was 4-fold or higher, which was in accordance to the data seen at 
the mRNA level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3: VAF347 inhibits IL-4 + GM-CSF induced IL-6 protein production in Monomac1. 
 IL-6 protein was measured in supernatants of samples 24h after cytokine induction by ELISA. 
 
Further ELISA data for Interleukin-6 showed that IL-6 protein levels increased 48 hours after 
stimulation of MM1 cells with IL-4 + GM-CSF, reaching a concentration of 700pg/ml (Figure 
3.2.4). Still, two days after cytokine stimulation VAF347 was able to maintain its inhibitory effect 
on IL-6 production. At a concentration of 50nM VAF347 IL-6 protein was detectable at a 
concentration of approximately 130pg/ml, thus showing a 5-fold decreased IL-6 response in 
Monomac1 cells when compound was added. 
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Figure 3.2.4: VAF347 inhibits IL-4 + GM-CSF induced IL-6 protein production in Monomac1. IL-6 
protein was measured 48h after cytokine stimulation by ELISA. 
 
Collectively, these data showed that MM1 cells could be used for studying the molecular 
mechanisms underlying the inhibitory effects of VAF347 on IL-6 production. 
 
3.3 VAF347 induces CYP1A1 expression in Monomac1 
Genome wide gene expression profiling in CD40 antibody activated monocyte derived DCs in the 
presence or absence of VAF347 was performed in our laboratory. Comparing the expression pattern 
profiles of untreated versus VAF347 treated cells showed that VAF347 induced the expression of 
genes which are known to be regulated by the aryl hydrocarbon receptor (AhR), including the aryl 
hydrocarbon receptor repressor (AHRR) and cytochrome P450 1B1 (CYP1B1) (67). These data 
indicated a possible involvement of AhR in the mode of action of VAF347. 
Further experiments showed that VAF347 also induced cytochrome P450 1A1 (CYP1A1) 
expression in human peripheral monocytes (67) another AhR dependent gene. To answer the 
question whether VAF347 also induced CYP1A1 expression in Monomac1 cells, MM1 cells were 
stimulated with VAF34 alone or in the presence of IL-4 + GM-CSF for 24 hours before CYP1A1 
mRNA was measured by RT-PCR (2.3).  
As shown in Figure 3.3.1 VAF347 induced CYP1A1 gene expression in MM1 cells in a dose-
dependent fashion. When the cytokines IL-4+GM-CSF were added, the increase of CYP1a1 mRNA 
in the presence of VAF347 was even higher, an effect which was also seen in human peripheral 
monocytes (67). In contrast to primary monocytes IL-4 + GM-CSF on its own had only minimal 
effects on CYP1A1 mRNA expression in Monomac1 (Figure 3.3.1). 
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Figure 3.3.1: VAF347 induces CYP1A1 mRNA expression in Monomac1. In the presence of IL-4 + 
GM-CSF CYP1A1 expression by VAF347 is increased. CYP1A1 expression was measured 24h after 
stimulation by RT-PCR and normalized to eF-1 expression.  
 
3.4 TCDD and omeprazole have a similar activity profile in MM1 compared to VAF347 
Since VAF347 induced CYP1A1 expression, a gene which is classically induced by the activation 
of AhR signaling, it was interesting to investigate the biological effects of known AhR agonists in 
Monomac1 cells.  
First, the effects of the prototypical AhR ligand TCDD on Monomac1 cells were examined. MM1 
cells were stimulated with IL-4 + GM-CSF in the presence or absence of TCDD (2.7.6) for 24 
hours, before CYP1A1 expression was measured by RT-PCR (2.3).  
As shown in Figure 3.4.1 TCDD induced CYP1A1 gene expression in MM1 cells. The presence of 
IL-4 + GM-CSF enhanced the TCDD dependent magnitude of CYP1A1 induction in a dose-
dependent fashion, an effect which was already seen with VAF347 (3.3). 
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Figure 3.4.1: TCDD induces CYP1A1 mRNA expression in Monomac1 cells. The presence of IL-4 + 
GM-CSF enhanced the TCDD dependent magnitude of CYP1A1 induction. CYP1A1 mRNA expression 
was measured 24h after stimulation by RT-PCR and normalized to eF-1 expression. 
 
To answer the question whether TCDD could also inhibit IL-6 expression in Monomac1 cells, 
MM1 cells were stimulated with IL-4 + GM-CSF in the presence or absence of TCDD for 24 hours, 
before IL-6 mRNA was measured by RT-PCR (2.3). Interestingly, TCDD was able to inhibit the  
IL-4 + GM-CSF induced IL-6 response in Monomac1 cells at an even higher potency than 
VAF347, with an IC50 of approximately 80pM (Figure 3.4.2). TCDD on its own did not induce  
IL-6 mRNA expression. 
 
 
Figure 3.4.2: TCDD inhibits IL-4 + GM-CSF induced IL-6 mRNA synthesis in Monomac1. IL-6 
mRNA expression was measured 24h after stimulation by RT-PCR and normalized to eF-1 
expression. 
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Since TCDD, the prototypical ligand of AhR showed an identical biological activity in MM1 cells 
compared to VAF347, these results strongly suggested that activation of AhR is involved in the 
mode of action of VAF347. 
Another AhR agonist that has been extensively studied due to its application in the clinic is 
omeprazole. 
Omeprazole is used for the treatment of gastric ulcers and dyspepsia due to its activity as a proton 
pump inhibitor. At high concentration, omeprazole has been demonstrated to bind and activate 
AhR, thus leading to the induction of the CYP1A1 gene (82,83). Interestingly, omeprazole 
stimulated AhR activity seems to be species-specific, since omeprazole activates AhR only in 
human and not in mouse cells (138,139). 
To test the effect of omeprazole on CYP1A1 expression, Monomac1 were stimulated with IL-4 + 
GM-CSF in the absence or presence of omeprazole (2.7.6) for 24 hours before CYP1A1 mRNA 
levels were measured by RT-PCR (2.3). As shown in Figure 3.4.3 omeprazole induced the 
expression of CYP1A1 mRNA in MM1 cells. The potency of the drug was approximately 1000-
fold weaker than that of VAF347 in agreement with the literature as a weak AhR agonist. The 
presence of IL-4 + GM-CSF enhanced the omeprazole dependent magnitude of CYP1A1 levels, an 
effect that was already seen with VAF347 and TCDD.  
 
 
Figure 3.4.3: Omeprazole induces CYP1a1 expression in Monomac1. The presence of IL-4 + 
GM+CSF enhanced the magnitude of CYP1A1. RT-PCR for CYP1A1 mRNA 24 h after stimulation is 
shown. CYP1A1 expression was normalized to eF-1 expression.  
 
To examine the effect of omeprazole on IL-6 expression MM1 cells were stimulated with IL-4 + 
GM-CSF in the absence or presence of omeprazole for 24 hours, before IL-6 mRNA was measured 
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as described above. Similar to TCDD, omeprazole inhibited IL-4 + GM-CSF induced IL-6 mRNA 
expression in Monomac1 cells in a dose-dependent fashion in the µM range (Figure 3.4.4).  
 
 
Figure 3.4.4: Omeprazole inhibits IL-4 + GM-CSF induced IL-6 mRNA production in Monomac1. 
RT-PCR for IL-6 mRNA 24 h after stimulation is shown. IL-6 expression was normalized to eF-1 
expression.  
 
Collectively, these data strongly indicated that activation of AhR signaling is involved in the mode 
of action of VAF347, since the two AhR agonists TCDD and omeprazole display an identical 
activity profile in MM1 cells compared to VAF347.  
 
3.5 PMA induces IL-6 expression in Monomac1 cells 
Multiple stimuli including the cytokines TNF-α, IL-1β and IFN-γ as well as bacterial components 
such as LPS or the yeast cell wall component zymosan have been shown to induce IL-6 expression 
in various cell types. Furthermore, stimulation of murine DCs by engagement of CD40 has been 
shown to induce IL-6 expression (140).  
To answer the question whether IL-6 expression in Monomac1 cells was restricted to IL-4 +  
GM-CSF induction, MM1 cells (2.7.3) were stimulated with various stimuli (2.7.6) for 24 hours, 
before IL-6 mRNA expression was analyzed by RT-PCR (2.3). The RT-PCR results in Figure 3.5.1 
show that stimulation of Monomac1 cells with TNF-α, LPS + IFN-γ, IL-1β + IL-4, zymosan or IL-3 
+ IL-4 induced only very low levels of IL-6 mRNA compared to the IL-4 + GM-CSF induced IL-6 
response. VAF347 did not inhibit any of these stimuli in their ability to induce IL-6 expression 
(data not shown) indicating considerable specificity of VAF347. Stimulation of Monomac1 with 
mouse anti-human CD40 (α-CD40) antibodies and IL-4 (in combination with a crosslinking 
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antibody) induced low levels IL-6 mRNA expression. VAF347 reduced α-CD40/IL-4 induced IL-6 
mRNA expression only by two-fold or less at a concentration of 50nM (data not shown).  
 
 
 
 
Figure 3.5.1: IL-6 mRNA expression in Monomac1 cells 24h after stimulation with various stimuli. 
IL-6 mRNA expression was measured by RT-PCR and normalized to eF-1 expression. 
 
 
Phorphol esters such as phorbol 12-myristate 13-acetate (PMA) have been shown to induce IL-6 
mRNA expression in human monocytes (141). To analyze the effect of PMA on IL-6 expression 
MM1 cells were stimulated with PMA (2.7.6) in the absence or presence of VAF347 for 24 hours, 
before IL-6 mRNA expression was analyzed as described above.  
As demonstrated in Figure 3.5.2 PMA induced high levels of IL-6 mRNA which were usually 2-3 
fold higher compared to IL-6 levels of IL-4 + GM-CSF induced MM1 cells. VAF347 inhibited 
PMA induced IL-6 mRNA expression in a dose dependent fashion, with an IC50 of approximately 
5nM. This was comparable to the calculated IC50 of VAF347 in IL-4 + GM-CSF induced 
Monomac1 cells (3.2).  
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Figure 3.5.2: PMA induces IL-6 mRNA expression in Monomac1 cells. VAF347 inhibits IL-6 
induction by PMA in a concentration dependent fashion. The top row shows RT-PCR for IL-6 mRNA 
in cells that were induced with PMA or IL-4+ GM-CSF in the presence or absence of VAF347 for 24 
hours. IL-6 expression was normalized to eF-1 expression. In the lower graph IL-6 protein was 
measured in the supernatants from the same cells. 
 
ELISA (2.5) data showed that IL-6 protein was detectable in supernatants of Monomac1 cells at a 
concentration of 1000pg/ml, when stimulated with PMA for 24 hours (Figure 3.5.2). In the 
presence of VAF347, PMA induced IL-6 protein expression was inhibited in a dose-dependent 
fashion with an estimated IC50 of ~5nM. These results showed that also PMA induced IL-6 
expression in MM1 can be inhibited by VAF347. PMA is known to activate a plethora of different 
signal transduction pathways. Since the potency of VAF347 to inhibit PMA induced IL-6 was 
practically identical with that of IL-4+GM-CSF stimulated IL-6, it is possible that PMA activated a 
very similar chain of signaling events in MM1 than IL-4+GM-CSF.  
 
3.6 Functional AhR is necessary to mediate the biological phenotype of VAF347 
So far, all available data strongly indicated an involvement of the AhR signaling pathway in the 
biological activity of VAF347. To examine the role of AhR in the mode of action of VAF347 in 
more detail, two different approaches were selected. First, Monomac1 cells were infected with a 
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trans-dominant negative version of the AhR. Secondly, AhR gene expression was silenced by using 
the microRNA adapted short hairpin RNA (shRNAmir) interference technique. 
 
3.6.1 A trans-dominant negative AhR protein abolishes VAF347 activity 
As a first attempt to analyze the role of AhR in the mode of action of VAF347, Monomac1 cells 
were infected with a recombinant retrovirus expressing a truncated form of the AhR protein lacking 
the transactivation domain at the carboxyl-terminus (Figure 3.6.1.1.A). This truncated AhR protein 
has already been shown to act in a trans-dominant negative fashion before (142).  
 
 
 
 
Figure 3.6.1.1: A trans-dominant negative AhR protein. A) a truncated form of AhR containing only 
aa 1-515 and thus lacking the carboxyl-terminal transactivation domain was cloned into the retroviral 
expression vector pMX-pie. B) Ectopic over-expression of a truncated AhR (AhR515) in Monomac1 
cells. A western blot analysis is shown. At the left, the positions of the molecular weight standards are 
indicated with the size given in kDa. At the right the position of AhR515 is indicated. 
 
The truncated AhR protein, containing amino acids 1-515 and therefore named AhR515, was 
amplified by PCR from cDNA of MM1 cells (2.4.3.A) and cloned into the recombinant retroviral 
expression vector pMX-pie. The resulting plasmid pMX-pie-AhR515 allows for the simultaneous 
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expression of the truncated AhR and the marker protein GFP due to the presence of an internal 
ribosome entry site (IRES) element (2.4.3.B) (Figure 3.6.1.1.A). This allowed for the selection of 
MM1 cells successfully infected with the AhR truncation mutant based on GFP positivity (2.10.3). 
 
Ectopic over-expression of the trans-dominant negative AhR protein in Monomac1 cells was 
confirmed by western blot (2.6.3). In whole cell lysates of Monomac1 cells infected with pMX-pie-
AhR515 the trans-dominant negative AhR protein with a size of ~59 kDa was detectable, whereas 
empty vector infected cells did not express this protein (Figure 3.6.1.1.B). 
To analyze the biological activity of recombinant AhR515, Monomac1 cells over-expressing 
AhR515 were stimulated with IL-4 + GM-CSF in the presence or absence of VAF347 for 24 hours, 
before CYP1A1 mRNA expression was measured by RT-PCR (2.3).  
Indeed, the AhR515 protein acted as a trans-dominant negative repressor since induction of 
CYP1A1 expression by VAF347 was almost completely abrogated in Monomac1 cells over-
expressing the trans-dominant negative AhR (Figure 3.6.1.2).  In cells that were infected with 
empty vector VAF347 was still able to induce CYP1A1 expression. These results confirmed the 
expression of AhR515 and its biological function in MM1 to act as a trans-dominant negative 
repressor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1.2: A trans-dominant negative AhR protein ablates CYP1a1 induction in Monomac1 
cells. AhR515 acts in a trans-dominant negative fashion by blocking the induction of CYP1A1 
expression by VAF347. Vector = cells infected with parental retroviral vector. CYP1a1 expression 
was normalized to eF-1 expression. 
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To answer the question whether the inhibitory effect of VAF347 on IL-6 expression was still 
observed in MM1 cells expressing the trans-dominant negative AhR, MM1 cells infected with 
either empty vector or AhR515 where stimulated with IL-4 + GM-CSF in the presence or absence 
of VAF347 for 24 hours before IL-6 mRNA production was analyzed by RT-PCR (2.3). 
Interestingly, VAF347 was no longer able to inhibit the IL-4 + GM-CSF induced IL-6 response in 
MM1 cells expressing the trans-dominant negative AhR (AhR515) (Figure 3.6.1.3). In contrast, 
VAF347 still inhibited IL-4 + GM-CSF induced IL-6 mRNA expression in vector infected cells.  
To confirm these data at the protein level, IL-6 protein was measured by ELISA (2.5) in the 
supernatants from the same cells. Vector infected cells produced IL-6 at a concentration of 
approximately 160pg/ml after induction with IL-4 + GM-CSF. At a concentration of 50nM 
VAF347 IL-6 protein was detectable at a concentration of approximately 40pg/ml, thus inhibiting 
the IL-6 response by 4-fold in vector infected cells. In contrast, IL-6 protein production was no 
longer inhibited in MM1 cells expressing AhR515 (Figure 3.6.1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1.3: A trans-dominant negative AhR protein blocks the function of VAF347 to inhibit IL-
6 production in Monomac1 cells. The top row shows RT-PCR for IL-6 mRNA in control (vector) or 
AhR515 expressing cells that were induced with IL-4+ GM-CSF in the presence or absence of 
VAF347 for 24 hours. IL-6 expression was normalized to eF-1 expression. In the lower graphs IL-6 
protein was measured in the supernatants from the same cells. 
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Similar results were obtained when IL-6 expression was induced by PMA (data not shown). These 
results demonstrated that the AhR protein plays a key role in the mode of action by which VAF347 
mediates inhibition of IL-6 synthesis, since over-expression of a trans-dominant negative AhR 
protein completely abolished VAF347 activity. 
 
To further corroborate that AhR signaling activation can regulate IL-6 expression in MM1 cells the 
effects of TCDD on Monomac1 cells expressing the trans-dominant negative AhR were examined. 
MM1 cells infected with AhR515 protein or empty vector were stimulated with IL-4 + GM-CSF in 
the presence or absence of TCDD for 24 hours before IL-6 expression was analyzed by RT-PCR 
(2.3). As shown in Figure 3.6.1.4 TCDD inhibited IL-6 mRNA expression in vector infected MM1 
cells in a dose-dependent fashion. In contrast IL-6 expression was no longer inhibited in MM1 cells 
expressing a trans-dominant negative AhR (AhR515) protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1.4: The trans-dominant negative AhR515 protein blocks the function of TCDD to 
inhibit IL-6 production in Monomac1 cells. The top row shows RT-PCR for IL-6 mRNA in control 
(vector) or AhR515 expressing cells that were induced with IL-4+ GM-CSF in the presence or 
absence of TCDD for 24 hours. IL-6 expression was normalized to eF-1 expression. In the bottom 
row IL-6 protein was measured in the supernatants from the same cells. 
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These data were further confirmed by measuring IL-6 protein in the supernatants of the same cells 
by ELISA (2.5). In vector infected cells induced with IL-4 + GM-CSF, IL-6 protein was measurable 
at a concentration of approximately 130pg/ml, while in the presence of 10nM TCDD the IL-6 
protein was reduced to a level of around 40pg/ml (Figure 3.6.1.4). This effect was no longer seen in 
MM1 cells expressing AhR515, since TCDD did not inhibit IL-6 production in these cells. 
 
Collectively, these data demonstrated that functional AhR protein is necessary to mediate the 
inhibitory effect of VAF347 on IL-6 production, since over-expression of a trans-dominant negative 
AhR completely abolished both VAF347 and TCDD activity in MM1 cells.  
 
3.6.2 Silencing of AhR gene expression abolishes VAF347 activity 
Another approach to analyze the functional involvement of the AhR in the mode of action of 
VAF347 was to silence wild type AhR gene expression. This was achieved by using the microRNA 
adapted short hairpin RNA (shRNAmir) interference technique. MicroRNAs are small endogenous 
RNAs that play important regulatory roles in animals by targeting mRNAs for cleavage or 
translational repression, thus reducing target gene expression (143).  
The human packaging cell line PhoenixGP (2.7.5), was used to generate retroviral virus particles by 
transfecting PhoenixGP cells with either LMP-sh-RNA control vector (sh-control) or LMP-sh-AhR 
construct (2.6.4) which both contained an internal ribosome entry site (IRES)-GFP element. 
Retroviral infection of Monomac1 cells was achieved as described above. After infection 
Monomac1 cells expressing high levels of GFP were sorted (2.10.3) and kept in medium (2.7.3) 
supplemented with 1 µg/ml puromycin as a selection marker. 
 
To test the functional activity of the LMP-sh-AhR construct, AhR protein expression in MM1 cells 
was analyzed by western blot (2.6.3). In whole cell lysates of Monomac1 cells infected with a sh-
control construct wild type AhR protein with a size of approximately ~110 kDa was detectable 
(Figure 3.6.2.1.A). In contrast, AhR protein expression was strongly reduced in MM1 cells infected 
with the LMP-sh-AhR construct. 
To analyze the biological consequences of AhR gene silencing, MM1 cells infected with either sh-
control or sh-AhR were stimulated with IL-4 + GM-CSF in the presence or absence of VAF347 for 
24 hours, before expression of the CYP1A1 or IL-6 gene was measured by RT-PCR (2.3).  
As seen in Figure 3.6.2.1.B CYP1A1 mRNA response to VAF347 was nearly completely 
abrogated in Monomac1 cells infected with the sh-AhR construct, whereas VAF347 normally 
induced CYP1A1 expression in cells infected with a sh-control construct. 
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Figure 3.6.2.1: Silencing of the AhR gene abolishes VAF347 activity. A) Reduced expression of AhR 
protein in Monomac1 cells infected with sh-AhR. A western blot analysis is shown. At the left, the 
positions of the molecular weight standards are indicated with the size given in kDa. At the right the 
position of AhR is indicated. 
B) The top row shows RT-PCR for CYP1A1 mRNA in sh-control (vector) or sh-AhR infected cells that 
were induced with IL-4+ GM-CSF in the presence or absence of VAF347 for 24 hours. In the bottom 
row IL-6 mRNA expression in the same samples is shown. CYP1A1 and IL-6 expression were 
normalized to eF-1 expression. Statistical analysis was done with two tailed Student’s t-test. 
 
More importantly, VAF347 was no longer able to inhibit IL-4 + GM-CSF induced IL-6 production 
in cells infected with sh-AhR (Figure 3.6.2.1.B). 
In summary, these data identified the AhR as a functional relevant target for VAF347 since 1) other 
AhR agonists displayed an identical activity profile in MM1 cells compared to VAF347, 2) over-
expression of a trans-dominant negative AhR completely abrogated VAF347 or TCDD activity and 
3) silencing of the AhR gene was sufficient to abolish VAF347 activity. 
 
3.7 Signaling events in Monomac1 after cytokine stimulation 
Very little is known about the intracellular signaling events that lead to induction of IL-6 expression 
in Monomac1 cells. In order to analyze in detail how VAF347 activated AhR interferes with IL-6 
expression in this cell line a thorough understanding of the signaling chains eventually leading to 
IL-6 expression in response to IL-4+GM-CSF was required.  
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3.7.1 IL-4 + GM-CSF lead to activation of members of the JAK/STAT family  
Cytokines often mediate their responses through activation of the JAK/STAT pathway (144). The 
STAT family is known to consist of seven members STAT1-5, STAT5a, STAT5b and STAT6. 
JAKs represent a family of four tyrosine kinases, JAK1, JAK2, JAK3 and Tyk2, that selectively 
phosphorylate STATs upon binding of cytokines to their respective receptors. In unstimulated cells, 
STATs reside inactive in the cytoplasm. Cytokine stimulation leads to JAK mediated 
phosphorylation of STATs. Upon phosphorylation STATs form homo- or heterodimers and 
translocate to the nucleus where they regulate the expression of their target genes. IL-4 and IL-13 
signaling is tightly connected to activation of STAT6 via activation of JAK1 and JAK3, and plays a 
key role in polarization of naïve CD4+ T cells towards a TH2 cell type (145). STAT5 is activated by 
multiple cytokines including IL-2, IL-3, IL-5 and GM-CSF, with GM-CSF signaling through JAK2 
(146,147). 
 
To examine which STATs were activated by IL-4+GM-CSF, Monomac1 cells were stimulated with 
the cytokine cocktail and the phosphorylation status of different STAT proteins was examined by 
western blotting: For this and all other following signaling experiments fresh Monomac1 cells 
(2.7.3) were seeded into 24 well plates at a density of 3x105 cells per well and incubated at different 
time points in the presence or absence of the cytokines IL-4 and GM-CSF (2.8.2). Samples 
containing VAF347 were pre-incubated with 50nM VAF347 30-60 minutes prior to cytokine 
stimulation (2.8.2). Then whole cells lysates were prepared (2.6.1). 50µg protein of each lysate 
sample were used for western blot analysis, starting with Tris-glycine gel electrophoresis followed 
by blotting of the gel to a nitrocellulose membrane (2.6.2). Activated STATs were detected with 
antibodies recognizing phosphorylated STATs while the total amount of STAT protein on the gel 
was measured using mABs recognizing activated and quiescent protein (2.6.4). 
The western blot analysis shown in Figure 3.7.1.1 demonstrated that stimulation of Monomac1 
with IL-4 + GM-CSF for 10 and 60 min lead to phosphorylation of STAT5 (Tyrosine694). Addition 
of VAF347 did not alter the phosphorylation status of STAT5. 
Similar results were obtained when STAT6 protein expression was analyzed: IL+4 and GM-CSF in 
combination lead to phosphorylation of STAT6 (Tyrosine641) 10 min and 60 min after cytokine 
induction. VAF347 did not change the phosphorylation level of STAT6 (Figure 3.7.1.1). 
 
 
 
 
Results 
 66
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.1.1: IL-4 + GM-CSF lead to phosphorylation of STAT5 and STAT6. Total protein 
fraction of Monomac1 cells was isolated and the expression of phosphorylated and non-
phosphorylated STAT proteins was determined in the same samples using western blotting.. At the left 
the molecular weight is indicated with the size given in kDa. At the right, positions of STAT proteins 
are indicated.  
 
The phosphorylation status of STAT1 and STAT3 proteins in MM1 cells after stimulation with IL-4 
+ GM-CSF was also examined by western blotting. Neither phosphorylated STAT1 nor 
phosphorylated STAT3 proteins could be detected (data not shown).  
These results did not give any information whether activation of the JAK/STAT pathway was 
necessary for the induction of IL-6 expression in Monomac1 cells. An approach to examine a 
possible involvement of the JAK/STAT cascade in the signaling pathway(s) that leads to induction 
of IL-6 expression, was to inhibit members of the JAK/STAT family. The JAK inhibitor  
CP-690,550 has been shown to selectively inhibit JAK-3 previously and is 20- to 100-fold less 
potent for JAK2 (148).  
Monomac1 cells (2.7.3) were stimulated with IL-4 + GM-CSF in the presence or absence of  
CP-690,550 for 24 hours, before IL-6 expression was analyzed by RT-PCR (2.3). Interestingly,  
CP-690,550 inhibited IL-6 mRNA induction by IL-4 + GM-CSF in a concentration dependent 
fashion with an IC50 of approximately 4nM (Figure 3.7.1.2). These results suggested that activation 
of JAK-3 was necessary for the induction of IL-6 expression in Monomac1.  
 
 
 
phospho STAT5
10 min
92 STAT5
100
phospho STAT6
STAT6
kD 
60 min
IL-4/GM-CSF
VAF347
    -       +       +        -       +      +
    -        -       +        -       -       +
Results 
 67
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.1.2: The JAK inhibitor CP-690,550 ablates IL-6 induction in Monomac1 cells. RT-PCR 
data shown. IL-6 expression was normalized to eF-1 expression. 
 
3.7.2 IL-4 + GM-CSF lead to activation of proteins of the MAP Kinase cascade  
GM-CSF is a hematopoietic cytokine that has important regulatory functions on cell proliferation 
and apoptosis in cells of myeloid, erythroid and lymphoid lineages (149,150). GM-CSF has been 
shown to induce multiple signaling pathways that transduce critical cell growth, differentiation or 
anti-apoptotic signals from the cell membrane into the nucleus. A common pathway triggered by 
GM-CSF is the Ras/Raf/MEK/ERK cascade. Many of the members of this pathway were initially 
identified as proto-oncogenes, and aberrant activation of this pathway has often been observed in 
malignantly transformed cells.  
Activation of the Ras/Raf/MEK/ERK cascade may lead to the phosphorylation and thus activation 
of mitogen-activated protein kinases (MAPKs). MAPKs trigger a variety of cellular programs 
including cell proliferation, cell differentiation and cell death and are activated by a variety of  
up-stream signals including growth and neurotrophic factors, cytokines hormones and also 
infectious agents such as LPS. In mammals there are three main families of MAPKs: the c-Jun 
NH2-terminal kinases (JNKs), p38 MAPK (p38) and extracellular-signal-regulated kinases (ERKs).  
The JNK pathway contains two isoforms of the c-Jun NH2-terminal kinase which phosphorylate 
multiple downstream targets such as the transcription factors c-Jun, ATF-2 and Elk-1 (151). 
To test a possible involvement of the JNK pathway for IL-6 expression Monomac1 were induced 
with IL-4 and GM-CSF in the presence of the JNK inhibitor SP600125. Inhibition of JNK did not 
have any effect on the IL-6 response (data not shown), suggesting that the JNK pathway is not 
needed for the induction of IL-6 synthesis in MM1. 
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Activation of the p38 signaling cascade leads to phosphorylation of various transcription factors 
such as ELK-1, ATF-2, CHOP and Sap1a as well as other downstream kinases. However, inhibition 
of p38 signaling with a specific compound available in house did not interfere with IL-4 + GM-CSF 
induced IL-6 expression (data not shown). 
The third MAP kinase pathway includes the two kinases p44 (ERK1) and p42 (ERK2). 
Activation of the MAP kinases leads to the phosphorylation of threonine and tyrosine residues of 
p44 MAP kinase (ERK1) and p42 MAP kinase (ERK2) at the sequence Thr*GluTyr by the 
upstream mitogen-activated protein kinase/ERK kinase (MEK). Phosphorylated and thus activated 
p44 and p42 MAP kinases can directly phosphorylate a series of transcription factors including  
Ets-1, c-Jun and c-Myc.  
To examine the phosphorylation status of p44/p42 MAP kinases in MM1 following cytokine 
stimulation, MM1 cells (2.7.3) were stimulated with IL-4, GM-CSF or a combination of both for  
5 or 20 min, before whole cell lysates were prepared (2.6.1) and western blotting was performed 
(2.6.2). To detect p44 and p42 MAP kinases either antibodies directed against total p44/p42 MAP 
kinases or antibodies directed against phosphorylated p44/p42 MAP kinases 
(Threonin202/Tyrosine204) were used (2.6.5). 
As seen in Figure 3.7.2.1 Monomac1 cells constitutively express p44/p42 MAP kinases. 
Stimulation of Monomac1 with IL-4 did not activate ERK phosphorylation while GM-CSF lead to 
low levels of transient ERK activation after 5 minutes which decayed at 20 minutes. The 
combination of both cytokines resulted in robust phosphorylation of p44/p42 MAP kinases which 
was stronger at 5 minutes. Thus, IL-4 and GM-CSF synergistically induced ERK1/2 
phosphorylation. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.2.1: IL-4 + GM-CSF lead to phosphorylation of p44/p42 MAP kinases. Total protein 
fraction of Monomac1 cells was isolated and the expression of phosphorylated and non-
phosphorylated p44 and p42 MAP kinases was determined in the same samples using western blotting. 
At the right, positions of p44/p42 kinases are indicated. 
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To examine the effects of VAF347 on the phosphorylation levels of p44/p42 MAP kinases, 
Monomac1 cells were stimulated with IL-4 + GM-CSF in the absence or presence of VAF347 for 
different time points (2.8.2). In a first series of experiments the presence of VAF347 seemed to 
increase and prolong the phosphorylation level of p44/p42 MAP kinases by IL-4 + GM-CSF. 
However, this effect was not reproducible (Figure 3.7.2.2).  
 
 
 
 
 
 
 
 
 
Figure 3.7.2.2: VAF347 does not reproducibly alter phosphorylation of p44/p42 MAP kinases. Total 
protein fraction of Monomac1 cells was isolated and the expression of phosphorylated and non-
phosphorylated p44 and p42 MAP kinases was determined in the same samples using western blotting. 
Only untreated control for 20 min is shown. At the right, positions of p44/p42 kinases are indicated. 
 
Earlier results showed that activation of the JAK/STAT pathway was involved in the signaling 
events that lead to IL-6 expression in Monomac1 cells (3.7.2). To test a possible link between the 
JAK/STAT pathway and the MAP kinase cascade MM1 cells (2.7.3) were stimulated with  
IL-4 + GM-CSF in the absence or presence of the JAK-3 inhibitor CP-690,550 and/or VAF347 for 
20 min (2.8.2), before western blot for p44/p42 MAP kinases was performed. 
In the presence of 20nM CP-690,550 stimulation of Monomac1 cells with IL-4 + GM-CSF lead to 
reduced phosphorylation of p44/p42 MAP kinases compared to cells that were induced with IL-4 + 
GM-CSF alone (Figure 3.7.2.3). VAF347 had no effect on the phosphorylation status of p44/p42 
MAP kinases in cells treated with CP-690,550. VAF347 alone did not lead to phosphorylation of 
p44/p42 MAP kinases. 
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Figure 3.7.2.3: The JAK-3 inhibitor CP-690,550 inhibits the phosphorylation of p44/p42 MAP 
kinases. Total protein fraction of Monomac1 cells was isolated and the expression of phosphorylated 
and non-phosphorylated p44 and p42 MAP kinases was determined in the same samples using western 
blotting. At the right, positions of p44/p42 kinases are indicated. 
 
These data demonstrated that activation of JAK-3 and maybe JAK2 was necessary for the 
phosphorylation of p44/p42 MAP kinases. However, these findings did not give information if 
activation of the MAP Kinase pathway was necessary for the induction of IL-6 expression in 
Monomac1 cells. One approach to examine a possible involvement of the p44/p42 MAP kinase 
cascade was to inhibit members of the MAP kinase family. PD98059 has been described to be a 
specific inhibitor of p44/p42 MAP kinases by inhibiting phosphorylation of these kinases (152). To 
test the biological activity of PD98059 in our experimental system, MM1 cells (2.7.3) were 
stimulated with IL-4+GM-CSF in the absence or presence of PD98059 for 20 min (2.8.2), before 
the phosphorylation levels of p44/p42 MAP Kinase were analyzed by western blotting (2.6.5). 
 
 
 
 
 
 
 
 
 
Figure 3.7.2.4: The MAP kinase inhibitor PD98059 inhibits the phosphorylation of p44/p42 MAP 
kinases. Total protein fraction of Monomac1 cells was isolated and the expression of phosphorylated 
and non-phosphorylated p44 and p42 MAP kinases was determined in the same samples using western 
blotting. At the right, positions of p44/p42 kinases are indicated. 
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At a concentration of 10µM PD98059 inhibited phosphorylation of p44/p42 MAP kinases in MM1 
cells that had been induced with IL-4 + GM-CSF for 20 min (Figure 3.7.2.4). 
 
To examine the effect of PD98059 on IL-6 expression Monomac1 cells were stimulated with IL-4 + 
GM-CSF in the absence or presence of PD98059 for 24 hours, before IL-6 expression was analyzed 
by quantitative RT-PCR (2.3). As shown in Figure 3.7.2.5 PD98059 inhibited IL-4 + GM-CSF 
induced IL-6 mRNA expression in a concentration dependent-fashion in MM1 cells. These data 
suggested that activation of p44/p42 MAP kinases is involved in the signal events that lead to IL-6 
expression in MM1 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.2.5: The MAP kinase inhibitor PD98059 inhibits IL-6 expression in Monomac1 cells.  
IL-6 expression was measured 24h after stimulation by RT-PCR and normalized to eF-1 expression. 
 
3.7.3 Goe6979, a potent JAK-2 inhibitor, inhibits IL-6 expression in Monomac1  
The protein kinase C (PKC) family of serine/threonine kinases has been shown to be a predominant 
downstream target of LPS signaling. The PKC family consists of at least 11 known isoforms that 
are divided into three subfamilies according to their substrate specifity: the conventional α, βI, βII 
and γ PKC which are dependent on calcium and diacylglycerol (DAG), the novel δ, ε, θ, and η PKC 
which are DAG dependent and calcium independent and finally the atypical ξ and λ/ι PKC which 
are DAG independent (153). PKC has been shown to be involved in the LPS induced production of 
TNF-α, IL-1β and IL-6 in monocytes and macrophages as well as the differentiation of immature 
cells into monocytes and macrophages (154,155). 
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To test a possible involvement of PKC proteins in the signaling events that lead to IL-6 synthesis, 
different PKC inhibitors were tested in their ability to block IL-6 expression in MM1. MM1 cells 
were stimulated with IL-4 + GM-CSF in the absence or presence of different PKC inhibitors (2.7.6) 
for 24h before IL-6 mRNA was measured as described above. As shown in Figure 3.7.3.1 neither 
Calphostin C, BisindolylmalmeideI nor Ro-32-0432 inhibited IL-4 + GM-CSF induced IL-6 mRNA 
expression in MM1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.3.1: Different PKC inhibitors do not alter IL-4/GM-CSF induced IL-6 expression in 
Monomac1. IL-6 mRNA expression was measured by RT-PCR and normalized to eF-1 expression. 
 
In contrast, the PKC inhibitor Goe6976 inhibited the IL-6 response to IL-4 + GM-CSF in a dose-
dependent fashion as shown in Figure 3.7.3.2. In addition to block PKC this compound was shown 
to act as potent inhibitor of JAK2 in the nanomolar range (156).  
 
Based on the negative data with the other PKC inhibitors and the known role of JAK2 in cytokine 
signaling it is plausible that the inhibitory effects of Goe6976 on IL-6 production was rather due to 
its anti-JAK2 activity rather than to its inhibitory effects on PKC. This concept would fit to the 
results obtained with the dual JAK3/JAK2 inhibitor CP-690,550 which also inhibited cytokine 
induced IL-6 expression. 
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Figure 3.7.3.2: The PKC inhibitor Goe6976, which is also a potent JAK-2 inhibitor, ablates  
IL-4/GM-CSF induced IL-6 expression in Monomac1. IL-6 mRNA expression was measured by  
RT-PCR and normalized to eF-1 expression. 
 
 
These results demonstrated that induction of IL-6 expression in Monomac1 does not involve PKC, 
since various PKC inhibitors did not reduce the IL-6 response to IL-4 + GM-CSF stimulation.  
 
 
3.7.4 NF-κB inhibitors do not alter IL-6 expression in Monomac1  
NF-κB has been shown to be involved in the events that lead to induction of IL-6 expression in 
various cell types. To investigate if inhibition of NF-κB could abolish the induction of IL-6 
synthesis in Monomac1, the two NF-κB inhibitors pyrrolidinedithiocarbamate and an “NF-κB 
activation inhibitor” (with a calculated IC50 of 11 nM in Jurkat cells) (2.7.6) were used.  
MM1 cells were stimulated with IL-4 + GM-CSF in the presence or absence of these two NF-κB 
inhibitors for 24h before IL-6 expression was measured as described above. As shown in Figure 
3.7.4.1 neither pyrrolidinedithiocarbamate nor the “NF-κB activation inhibitor” could inhibit IL-4 + 
GM-CSF induced IL-6 expression in Monomac1.  
These results suggested that NF-κB activation was not critically involved in the signaling events 
that lead to induction of IL-6 expression in MM1 cells. 
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Figure 3.7.4.1: NF-κB inhibitors do not alter IL-4/GM-CSF induced IL-6 expression in Monomac1. 
IL-6 mRNA expression was measured by RT-PCR and normalized to eF-1 expression. 
 
 
3.8 IL-6 promoter studies 
IL-6 expression can be induced by a variety of cell stimuli and different mechanisms may act 
individually to enhance IL-6 transcription, depending on the stimulus and cell type. So far, several 
regulatory elements in the IL-6 promoter have been described, including cis-regulatory elements for 
the transcription factors NF-IL6, NF-κB, CREB and AP-1.  
So far, all available data indicated functional involvement of the AhR in the mode of action of 
VAF347. AhR has been shown to physically interact with other transcription factors, including  
NF-κB (157). Therefore, a possible explanation for the inhibitory activity of VAF347 on IL-6 
mRNA may be that activation of AhR signaling interferes with IL-6 promoter activity as a 
consequence of AhR interaction with a transcription factor necessary for promoter activation.  
 
3.8.1 VAF347 inhibits the induction of an IL-6 promoter reporter construct 
To investigate the possibility that VAF347 activity interferes with IL-6 expression at the 
transcriptional level, an ~800bp IL-6 promoter fragment was cloned upstream of the reporter gene 
luciferase into the vector pGL3-basic (2.4.1). This construct, which was named ‘pGL3b-IL-6 
promoter’, was transiently transfected into Monomac1 cells by electroporation using the Amaxa 
Nucleofector device™ (2.9). Briefly, 2x106 Monomac1 cells were resuspended in nucleofection 
Solution-V containing ‘pGL3b-IL-6 promoter’ or empty vector, before cells were electroporated in 
the Amaxa Nucleofector device™. Cells were then stimulated with either PMA or IL-4+GM-CSF 
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in the presence or absence of VAF347 or VAG005 for 24 hours, before luciferase activity as a 
function of IL-6 promoter activity was measured in lysed cells (2.9.1). 
 
As shown in Figure 3.8.1.1 the presence of the IL-6 promoter resulted in higher constitutive 
expression of luciferase in untreated Monomac1 cells compared to vector transfected cells. The 
stimulation of pGL3b-IL-6 promoter transfectants with PMA increased reporter gene expression 
about 7-fold, while IL-4 + GM-CSF lead to 5-fold increase of reporter gene expression. 
Interestingly, the presence of VAF347 in both PMA or IL-4 + GM-CSF induced transfectants 
inhibited luciferase gene expression by either ~2.6–fold or 3-fold, respectively.  
VAG005 is a closely related derivative of VAF347 which was found to be inactive on human  
B-cells to inhibit IgE production (67) and is only a weak ligand of AhR, with a binding potency of 
at least 100- fold less compared to VAF347. In contrast to VAF347, VAG005 did not inhibit 
luciferase gene induction in PMA or IL-4 + GM-CSF treated cells. 
These data demonstrated that VAF347 signaling interferes with IL-6 expression at the 
transcriptional level, since VAF347 inhibits induction of an IL-6 promoter reporter construct. In 
contrast, VAG005, a much weaker ligand for AhR does not inhibit reporter gene expression. This is 
in line with earlier data of AhR being critically involved in suppression of the IL-6 response. 
 
 
 
Figure 3.8.1.1: VAF347 inhibits reporter gene expression of a IL-6 promoter construct. Transient 
transfection of Monomac1 cells with an IL-6 promoter construct. As negative control the empty vector 
(vector) was used. One representative experiment out of three is shown. 
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3.8.2 VAF347 blocks the binding of NF-IL6 to the IL-6 promoter 
A possible mechanism by which VAF347 could mediate inhibition of IL-6 expression at the 
transcriptional level is that VAF347 somehow alters the transcription factor composition binding to 
the IL-6 promoter DNA sequence. To determine whether transcription factors known to be 
important for the transcription of IL-6, bind to the IL-6 promoter chromatin immunoprecipitation 
(ChIP) assays were performed. The ChIP technique allows to examine whether a known 
transcription factor truly binds to a regulatory DNA sequence in living cells: live cells are treated 
with formaldehyde to generate protein-protein and protein-DNA cross-links between molecules in 
close proximity. Crosslinked nucleoprotein complexes containing the transcription factor of interest 
are then enriched by immunoprecipitation with anti-transcription factor specific antibodies. 
Reversal of the formaldehyde protein-DNA cross-links permits recovery and quantitative analysis 
of the co-immunoprecipitated DNA.  
Briefly, Monomac1 cells were stimulated with IL-4 + GM-CSF in the presence or absence of 
VAF347 for 24 hours (2.11.1). Crosslinking of histones to DNA was achieved by the addition of 
formaldehyde to the cells at a final concentration of 0.7%, followed by lysis of the cells in SDS 
Lysis buffer (2.11.2). Random DNA fragmentation was done using the Diagenode Bioruptor 
machine. In 10 cycles of sonication, 30 sec each, the DNA was fragmented to a length of 100-400bp 
fragments (2.11.3). At this point aliquots of each sheared DNA sample were stored and labelled as 
Input to control the quality of the DNA.  
Then, immunoprecipitation was performed by adding anti human NF-IL6 antibody or IgG control 
antibody to each ChIPsample (2.11.4). Following immunoprecipitation the DNA-histone complexes 
were eluted from the NF-IL6 antibody and Proteinase K digestion was performed (2.11.5). DNA was 
recovered by Phenol/Choroform extraction, followed by direct analysis of the DNA by PCR with 
primers amplifying the NF-IL6 binding region in the IL-6 promoter (2.11.6).  
As shown in Figure 3.8.2.1 a 130bp IL-6 promoter product was obtained in IL-4 + GM-CSF induced 
Monomac1 cells using the NF-IL6 antibody. 
Interestingly, in the presence of VAF347 the IL-6 promoter product was not seen in Monomac1 cells 
that were induced with IL-4 + GM-CSF.  
In control samples that were immunoprecipitated without anti-NF-IL6 or with control antibody (rabbit 
IgG), DNA-protein complexes did not generate the IL-6 promoter PCR product (Figure 3.8.2.1).  
These studies demonstrated that IL-4 + GM-CSF induce the binding of NF-IL6 to the IL-6 promoter 
while in the presence of VAF347 NF-IL6 does not bind to the IL-6 promoter.  
Results 
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Figure 3.8.2.1: Binding of NF-IL6 to the IL-6 promoter in activated Monomac1 cells. MM1 were 
stimulated with IL-4+GMCSF in the absence or presence of VAF347 for 24, before samples were 
subjected to ChIP analysis. DNA-protein complexes were immunoprecipitated without (-) or with anti-
NF-IL6 (α-NF-IL6) or control antibodies (rabbit-IgG). The specific IL-6 promoter 130bp product is 
indicated. In addition the quality of the input DNA (Input) was controlled by PCR. One representative 
experiment out of two is shown. 
 
 
3.8.3 VAF347 does not inhibit the expression of IL-6 relevant transcription factors 
A possible mechanism by which VAF347 could block the binding of NF-IL6 to the IL-6 promoter 
is that VAF347 alters the expression of NF-IL6 or other transcription factors necessary for the 
induction of IL-6 gene transcription. To examine the expression levels of NF-IL6, NF-κB p65 and 
c-Fos or c-Jun, MM1 cells were stimulated with IL-4 + GM-CSF in the presence or absence of 
VAF347 before mRNA expression was examined by RT-PCR (2.3).  
As shown in Figure 3.8.3.1 VAF347 did not inhibit the expression of NF-IL6, NF-κB p65, c-Fos or 
c-Jun in MM1 cells that were induced with IL-4 + CM-CSF. 
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Figure 3.8.3.1: VAF347 does not inhibit the expression of transcription factors which are thought to 
be relevant in IL-6 transcription in Monomac1. The top row shows RT-PCR for c-Jun and c-Fos 
mRNA in MM1 cells that were induced with IL-4/GM-CSF in the presence or absence of VAF347 for 
24 hours. The bottom row shows mRNA expression levels of NF-κB p65 and NF-IL6. Expression was 
normalized to eF-1 expression. 
 
 
These results suggested that the inhibitory effect of VAF347 is not mediated via reduced expression 
of transcription factors which are thought to be relevant for the induction of IL-6 expression. 
 
3.9 Interference of VAF347 with IL-6 relevant transcription factors 
So far, all available data indicated that VAF347 interfered with IL-6 expression at the 
transcriptional level, since VAF347 inhibited the expression of an IL-6 promoter reporter construct 
and blocked the binding of NF-IL6 to the IL-6 promoter as seen in ChIP assays. 
In order to substantiate the effects of VAF347 on NF-IL6 promoter interaction, the transcription 
factor was overexpressed in MM1 cells. The rationale for this approach was the possibility that 
VAF347 activated AhR exerted its regulatory effects by interaction with crucial transcription 
factors driving IL-6 expression (such as NF-IL6). In such a scenario, over-expression of a potential 
AhR partner protein to levels higher than endogenous AhR would still leave enough unliganded 
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factor available to perform its normal function. Consequently, one would expect a loss of VAF347 
potency. To investigate if over-expression of either wild-type NF-κB p65, NF-IL6 or AP-1 could 
abolish the inhibitory effect of VAF347 in Monomac1 cells, each transcription factor was cloned 
into the retroviral expression vector pMX-pie. 
As a first attempt, Monomac1 cells were retrovirally infected with the pMX-pie expression vector 
containing full-length c-Fos or c-Jun proteins, both components of the transcription factor AP-1. 
However, MM1 cells over-expressing c-Fos or c-Jun respectively were not viable and died shortly 
after infection, probably due to intolerance of MM1 cells to high amounts of c-Fos/c-Jun. 
Therefore, interference of VAF347 with AP-1 activity could not be examined. 
 
3.9.1 Over-expression of NF-IL6 partially abolishes the inhibitory effect of VAF347 
The full-length NF-IL6 sequence was amplified from cDNA of human MM1 cells and cloned into 
the recombinant retroviral expression vector pMX-pie, which contained an internal ribosome entry 
site (IRES)-GFP element (2.4.5). This construct was named pMX-pie-NF-IL6. 
The human packaging cell line PhoenixA (2.7.4) was used to generate retroviral virus particles by 
transfecting PhoenixA cells with either the pMX-pie vector or pMX-pie-NF-IL6 (2.10.1).  
Retroviral infection of MM1 cells was done as described above. 
Ectopic over-expression of full length NF-IL6 protein in Monomac1 cells was confirmed by 
western blotting (2.6.6). Since the NF-IL6 gene encodes several isoforms due to usage of alternative 
AUG translational initiation sites, NF-IL6 isoforms of 40 kDa, 35 kDa, 20 kDa and 8.5 kDa can be 
produced.  
In whole cell lysates of MM1 infected with pMX-pie-NF-IL6 over-expression of NF-IL6 isoforms 
with a size of ~40 kDa and ~ 20 kDa was confirmed (Figure 3.9.1.1.A). 
To analyze the effect of NF-IL6 over-expression on the IL-6 response, MM1 cells over-expressing 
wild-type NF-IL6 were stimulated with IL-4 + GM-CSF in the presence or absence of VAF347 for 
24 hours, before IL-6 expression was measured by RT-PCR (2.3).  
As shown in Figure 3.9.1.1.B over-expression of NF-IL6 resulted in constitutive higher expression 
levels of IL-6 mRNA in untreated NF-IL6 infectants compared to vector infected cells. Induction 
with IL-4 + GM-CSF lead to increased levels of IL-6 mRNA in cells over-expressing NF-IL6. 
Interestingly, the inhibitory effect of VAF347 on IL-6 expression was partially abolished in MM1 
cells over-expressing NF-IL6. 
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Figure 3.9.1.1: Ectopic over-expression of the transcription factor NF-IL6 partially abolishes the 
inhibitory effect of VAF347 on IL-4 + GM-CSF induced IL-6 expression. A) Ectopic over-
expression of NF-IL6 protein in Monomac1 cells infected with pMX-NF-IL6. A western blot analysis is 
shown. At the left, the positions of the molecular weight standards are indicated with the size given in 
kDa. At the right the positions of NF-IL6 isoforms are indicated. 
B) The top row shows RT-PCR for IL-6 mRNA in vector (vector) or pMX-NF-IL6 (NF-IL6) infected 
cells that were induced with IL-4+ GM-CSF in the presence or absence of VAF347 for 24 hours. IL-6 
expression was normalized to eF-1 expression. In the bottom row IL-6 protein was measured in the 
supernatants of the same cells. 
 
To confirm these data on the protein level, IL-6 protein was measured in the supernatants of the 
same samples by ELISA (2.5). Constitutive expression of very low amounts of IL-6 close to the 
detection limit of the ELISA was measurable in NF-IL6 infectants but not in control cells (Figure 
3.9.1.1.B). Induction of NF-IL6 infectants with IL-4+GM-CSF lead to increased levels of IL-6 
protein compared to vector infected cells, which was is accordance to the results seen at the mRNA 
level. The presence of VAF347 in IL-4+GM-CSF induced NF-IL6 infectants showed consistently 
less inhibition of IL-6 levels compared to vector infected cells. The reduced degree of inhibition 
was statistically significant but the inhibitory effect of VAF347 was not completely abrogated.  
To test if the partial loss of VAF347 inhibitory activity was also seen with another induction 
stimulus of IL-6 expression, MM1 cells over-expressing wild-type NF-IL6 were stimulated with 
PMA in the presence or absence of VAF347 for 24 hours, before IL-6 mRNA expression was 
measured by quantitative RT-PCR (2.3).  
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As shown in Figure 3.9.1.2 the inhibitory effect of VAF347 on PMA induced IL-6 expression was 
partially abolished in MM1 cells over-expressing NF-IL6, while in vector infected cells VAF347 
inhibited IL-6 expression. Also at the protein level, the inhibitory activity of VAF347 was strongly 
abrogated in NF-IL6 infectants (Figure 3.9.1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.1.2: Over-expression of the transcription factor NF-IL6 partially abolishes the inhibitory 
effect of VAF347 on PMA induced IL-6 expression. The top row shows RT-PCR for IL-6 mRNA in 
vector (vector) or pMX-NF-IL6 (NF-IL6) infected cells that were induced with PMA in the presence or 
absence of VAF347 for 24 hours. IL-6 expression was normalized to eF-1 expression. In the bottom 
row IL-6 protein was measured in the supernatants of the same cells. 
 
 
Collectively, these data demonstrated that VAF347 mediates its inhibitory effect at least partially 
via interfering with NF-IL6, since VAF347 blocks the binding of NF-IL6 to the IL-6 promoter and 
over-expression of wild type NF-IL6 partially abolishes the inhibitory effect of VAF347. 
 
 
 
 
0
50
100
150
200
250
300
350
0
200
400
600
800
1000
1200
PMA
nil     0     50      5    0.5   nil     0      50     5    0.5    VAF347 (nM)
PMA 
IL
-6
 m
R
N
A
 
no
rm
al
iz
ed
 e
xp
r. 
(2
4h
)
IL
-6
 p
ro
te
in
 
(p
g/
m
l) 
vector NF-IL6
Results 
 82
3.9.2 Over-expression of NF-κB p65 does not alter the inhibitory effect of VAF347 
The wild type protein NF-κB p65 was amplified from cDNA of human Monomac1 cells and cloned 
into the recombinant retroviral expression vector pMX-pie (2.4.6). The resulting construct was 
named pMX-pie- NF-κB p65. 
Retroviral infection of Monomac1 cells with either vector or pMX-pie- NF-κB p65 was done as 
described above. Ectopic over-expression of full length NF-κB p65 protein was examined by 
western blotting (2.6.7). In whole cell lysates of MM1 cells infected with pMX-pie-NF-κB p65 
over-expression of full-length NF-κB p65 protein was confirmed (Figure 3.9.2.1.A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.2.1: Ectopic over-expression of the transcription factor NF-κB p65 does not alter the 
inhibitory effect of VAF347 on IL-6 expression. A) Ectopic over-expression of NF-κB p65 protein in 
Monomac1 cells infected with pMX-NF-κB p65. A western blot analysis is shown. At the left, the 
positions of the molecular weight standards are indicated with the size given in kDa. At the right the 
position of NF-κB p65 is indicated. 
B) IL-6 mRNA was measured by RT-PCR in vector (vector) or pMX-NF-κB p65 (NF-κB p65) 
infected cells that were induced with IL-4+ GM-CSF in the presence or absence of VAF347 for 24 
hours. IL-6 expression was normalized to eF-1 expression. 
 
The biological effect of NF-κB p65 over-expression on the IL-6 response was investigated by 
stimulation of MM1 cells with IL-4 + GM-CSF in the presence or absence of VAF347 for 24 hours. 
IL-6 expression was measured by RT-PCR (2.3). As seen in Figure 3.9.2.1.B NF-κB p65 infectants 
showed higher induction of IL-6 mRNA after IL-4 + GM-CSF stimulation than vector infected cells 
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consistent with the activating role of NF-B p65 in IL-6 gene regulation (17,21). However, 
VAF347 was not altered in is ability to inhibit IL-6 expression in MM1 cells over-expressing  
NF-κB p65. 
These results suggested that VAF347 mediates its inhibitory effect on IL-6 mRNA production 
independently of NF-κB p65, since over-expression of NF-κB p65 could not abrogate the inhibitory 
effect of VAF347. 
 
3.9.3 Silencing of the PU.1 gene abolishes the inhibitory effect of VAF347 
A previous study has demonstrated that NF-IL6 vigorously activates IL-1β gene expression in 
human HeLa cells via a protein-protein tether with the transcription factor Purine-rich box 1 (PU.1) 
(158). Transient transfection assays in PU.1 deficient HeLa cells showed that NF-IL6 strongly 
synergized with PU.1 on the IL-1β core promoter. Furthermore, Glutathione S-transferase (GST) 
pull-down protein-interaction assays demonstrated a physical interaction between the basic leucine 
zipper region of NF-IL6 and the winged helix-turn-helix (wHTH) DNA binding domain of PU.1. 
PU.1, also known as Spi-1, belongs to the family of ETS transcription factors which regulate the 
expression of a variety of genes that participate in diverse cellular activities including mitosis, 
apoptosis as well as the regulation of the immune system (159). PU.1 is expressed in mature 
macrophages, granulocytes and B cells as well as the immature precursors of these cell types (160) 
and is required for the development of myeloid and lymphoid cells.  
 
To analyze a possible involvement of the PU.1 gene in the mechanism that drives IL-6 expression 
in MM1 cells, the PU.1 gene was silenced by using the microRNA adapted short hairpin RNA 
(shRNAmir) interference technique (as described above).  
The human packaging cell line PhoenixGP (2.7.5), was used to generate lentiviral virus particles by 
transfecting PhoenixGP cells with either the GIPZ-sh-Control vector (sh-control) or a GIPZ-sh-
PU.1 construct, which both contained an internal ribosome entry site (IRES)-GFP element (2.10.2). 
This allowed for the selection of MM1 cells successfully infected with the sh-PU.1 construct based 
on GFP positivity. 
To test the functional activity of the GIPZ-sh-PU.1 construct, PU.1 protein expression in MM1 cells 
was analyzed by western blot (2.6.8). In whole cell lysates of Monomac1 cells infected with a sh-
control construct wild type PU.1 protein with a size of approximately 40 kDa was detectable 
(Figure 3.9.3.1.A). In contrast, PU.1 protein expression was strongly reduced in MM1 cells 
infected with the GIPZ-sh-PU.1 construct. 
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To analyze the biological consequences of PU.1 gene silencing, MM1 cells infected with either sh-
control or sh-PU.1 were stimulated with IL-4 + GM-CSF in the presence or absence of VAF347 for 
24 hours, before expression of the IL-6 gene was measured by RT-PCR (2.3).  
As seen in Figure 3.9.3.1.B IL-4 + GM-CSF still induced IL-6 expression in MM1 sh-PU.1 
infectants, although the maximal IL-6 response in these cells was strongly reduced compared to sh-
control infected cells. Interestingly, VAF347 was no longer able to inhibit the IL-4 + GM-CSF 
induced IL-6 response in MM1 cells infected with sh-PU.1, whereas in sh-control infected cells 
VAF347 still inhibited IL-6 expression.  
 
 
 
Figure 3.9.3.1: Silencing of the PU.1 gene partially abolishes VAF347 activity. A) Reduced 
expression of PU.1 protein in Monomac1 cells infected with sh-PU.1. A western blot analysis is 
shown. At the left, the positions of the molecular weight standards are indicated with the size given in 
kDa. At the right the position of PU.1 is indicated. 
B) IL-6 mRNA was measured by RT-PCR in sh-control (vector) or sh-PU.1 infected cells that were 
induced with IL-4+ GM-CSF (top row) or PMA (bottom row) in the presence or absence of VAF347 
for 24 hours. IL-6 expression was normalized to eF-1 expression. 
 
To test if the loss of the inhibitory effect of VAF347 on IL-4 + GM-CSF induced IL-6 expression in 
sh-PU.1 infectants was also observed after PMA stimulation, MM1 sh-PU.1 infected cells were 
stimulated with PMA in the presence or absence of VAF347 for 24 hours, before IL-6 mRNA levels 
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were measured by RT-PCR. As shown in Figure 3.9.3.1.B PMA induced IL-6 expression in sh-
PU.1 infectants, though the total level of IL-6 in response to PMA was strongly reduced in sh-PU.1 
infectants compared to sh-control infected cells. Interestingly, VAF347 inhibited PMA induced  
IL-6 expression in both MM1 sh-PU.1 and sh-control infectants to the same extent. 
 
Since the IL-6 levels in response to IL-4 + GM-CSF or PMA were strongly reduced in MM1 sh-
PU.1 infectants compared to sh-control cells, it was unclear whether this effect was due to overall 
reduced gene expression in MM1 cells infected with the sh-PU.1 construct. Therefore, the 
expression of CYP1A1 was determined by RT-PCR (2.3) in the same samples as shown in figure 
3.9.3.1. As shown in Figure 3.9.3.2 VAF347 induced CYP1A1 gene expression in both sh-control 
or sh-PU.1 infectants at comparable levels. 
 
 
 
Figure 3.9.3.2: Silencing of the PU.1 gene does not abolish VAF347 activity on CYP1A1 expression. 
CYP1A1 mRNA was measured by RT-PCR in sh-control (vector) sh-PU.1 infected cells that were 
induced with IL-4+ GM-CSF in the presence or absence of VAF347 for 24 hours. CYP1A1 expression 
was normalized to eF-1 expression. 
 
 
These additional data suggested that the reduced IL-6 expression levels in MM1 sh-PU.1 infectants 
resulted from a specific effect of PU.1 gene silencing and were not due to a general inhibitory effect 
on gene expression. Therefore, PU.1 might positively contribute to the induction of IL-6 mRNA 
synthesis in MM1 cells. 
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The inhibitory effect of VAF347 on IL-6 gene transcription was only abolished in IL-4 + GM-CSF 
but not in PMA induced MM1 sh-PU.1 infectants, suggesting different roles of PU.1 in IL-6 gene 
induction depending on the stimuli.  
 
To examine the effect of VAF347 on the expression level of the PU.1 gene, wild type MM1 cells 
were stimulated with IL-4 + CM-CSF in the presence or absence of VAF347 for 24 hours before 
PU.1 mRNA expression was examined by RT-PCR (2.3).  
As shown in Figure 3.9.3.3 VAF347 did not alter the expression levels of PU.1 in MM1 cells 
suggesting that the inhibitory effect of VAF347 is not mediated via altered expression of the 
transcription factor PU.1. 
 
 
Figure 3.9.3.3: VAF347 does not alter the mRNA expression level of the transcription factor PU.1. 
PU.1 mRNA was measured by RT-PCR in MM1 cells that were induced with IL-4+ GM-CSF in the 
presence or absence of VAF347 for 24 hours. PU.1 expression was normalized to eF-1 expression. 
 
 
 
 
 
- + +  - IL-4/GM-CSF 
- - +   +  VAF347 (50nM) 
0
100
200
300
400
500
600
700
800
no
rm
.  
ex
pr
. (
24
h)
PU.1
no
rm
.  
ex
pr
. (
24
h)
no
rm
.  
ex
pr
. (
24
h)
Discussion 
 87
4. DISCUSSION  
 
The aim of this study was the identification of the molecular target(s) of the novel 
immunomodulator VAF347 and its molecular mechanism of action in the human monocytic cell 
line Monomac1. First, we showed that IL-4 and GM-CSF in combination as well as PMA induced 
IL-6 mRNA and protein expression in MM1 cells. VAF347 inhibited both IL-4/GM-CSF and PMA 
induced IL-6 expression in a dose-dependent fashion, with an IC50 of approximately 5nM. In 
contrast to IL-6, the CYP1A1 gene was strongly induced by VAF347 in MM1. Since the CYP1A1 
gene is known to be induced by activation of AhR, a possible involvement of AhR in the mode of 
action of VAF347 was proposed.  
This hypothesis was verified at several levels: First, we showed that the prototypical AhR ligand 
TCDD as well as the AhR agonist omeprazole, a proton pump inhibitor, displayed similar activity 
profiles in MM1 compared to VAF347. Second, over-expression of a trans-dominant negative AhR 
(AhR515) was sufficient to abolish the inhibitory effect of VAF347 or TCDD on IL-6 expression. 
Third, silencing of endogenous AhR gene expression abrogated VAF347 activity. Collectively, 
these data identified the AhR as a critical molecular target involved in the mode of action of 
VAF347.  
Independent experiments in our laboratory confirmed the AhR as the essential functional target of 
VAF347: the compound competitively displaced ~50% of [3H]TCDD bound to AhR at a 
concentration of 10nM VAF347 Most importantly, the lack of AhR protein in homozygous AhR 
deficient mice led to unresponsiveness of VAG539 (a VAF347 analog) treatment in a model of 
pulmonary inflammation (67). 
 
Similar to VAF347, other AhR agonists have been shown to inhibit IL-6 expression. In a mouse 
bone marrow stromal cell line TCDD and 7,12-dimethylbenz[a]anthracene (DMBA) both 
selectively abrogated LPS induced IL-6 synthesis, possibly due to reduced binding of NF-κB to its 
recognition site in the IL-6 promoter in the presence of DMBA (161). Another study showed that 
the AhR agonist β-naphthoflavone disturbed cAMP-induced astrocyte differentiation of C6 rat 
glioma cells by inhibiting the production of IL-6, an important autocrine differentiation factor for 
these cells (162). 
 
With the identification of AhR as the critical molecular target for VAF347, the question was raised 
about the molecular mode of action by which AhR activation interfered with IL-6 expression in 
MM1 cells. 
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To investigate if de novo protein synthesis is necessary for the inhibitory effect of VAF347, we 
tested the effects of the translation inhibitor cycloheximide on IL-6 expression. Interestingly, 
cycloheximide on its own induced expression of IL-6 and high levels of the CYP1A1 gene. 
Cycloheximide as well as other translation inhibitors such as anisomycin and puromycin have been 
shown to induce CYP1A1 expression (163). This effect is possibly mediated by a cycloheximide-
sensitive factor that stabilizes AhR and prevents AhR degradation (164). Therefore, the question 
whether de novo protein synthesis is necessary for the inhibitory effect of VAF347 could not be 
answered and remains to be elucidated. 
 
Since very little was known about the intracellular events that trigger IL-6 expression in MM1 cells, 
we examined the role of different common cytokine signaling pathways known to contribute to the 
induction of cytokine synthesis. Stimulation of MM1 with IL-4 and GM-CSF lead to 
phosphorylation of STAT5 and STAT6 proteins. Inhibition of JAK2 and JAK3, both known to be 
involved in GM-CSF or IL-4 signaling respectively, abolished IL-6 expression in response to IL-4 + 
GM-CSF, demonstrating a functional involvement of the JAK/STAT pathway in the signal cascade 
that leads to induction of IL-6 synthesis in MM1.  
STAT5 has already been described to induce IL-6 expression in murine leukemic M1 cells (165). In 
these cells activation of STAT5 lead to enhanced binding of NF-κB p65 to the promoter region of 
IL-6 possibly via transactivation of NF-κB p65 by STAT5. To our knowledge no functional STAT 
responsive elements have been described in the IL-6 promoter. So far we can only speculate that 
activated STAT contributes to the signals that trigger IL-6 expression, for example via 
transactivation of other transcription factors relevant for IL-6 transcription. Pre-treatment of IL-4 
and GM-CSF stimulated MM1 cells with VAF347 did not change the level of STAT protein 
phosphorylation indicating that AhR activation did not interfere with receptor proximal signaling 
events of the JAK/STAT pathway. 
Furthermore, we showed that IL-4 and GM-CSF in combination lead to phosphorylation of p44/p42 
(ERK1 and ERK2) MAP kinases. Inhibition of p44/p42 MAP kinases with the MAPK inhibitor 
PD98059 abrogated IL-6 synthesis, demonstrating an involvement of p44/p42 MAP kinases in the 
signaling pathway that leads to IL-6 expression in MM1. Inhibition of JAK3 activity with  
CP-690,550 also inhibited phosphorylation of p44/p42 MAPK by IL-4/GM-CSF. These results 
demonstrated that ERK1/2 phosphorylation represented a critical step in the IL-4 and GM-CSF 
signaling chain for IL-6 expression in MM1 cells. In addition, ERK1/2 phosphorylation appeared to 
be dependent on JAK3 activation indicating that p44/p42 MAPK activation occurred downstream of 
JAK phosphorylation.  
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The p44/p42 MAP kinases have already been shown to be involved in IL-6 expression in human 
monocytes: in one study IL-6 expression induced by okadaic acid was abolished in the presence of 
the MAPK inhibitor PD98059, possibly due to reduced transcriptional activity of NF-κB (166). 
Another study showed that in human monocyte derived DCs LPS/lysophosphatidic acid induced  
IL-6 expression was dependent on activation of p44/p42 MAP kinases, since inhibition of p44/p42 
MAP kinases with PD98059 abolished the IL-6 response in these cells (167). 
VAF347 did not block IL-4+GM-CSF triggered ERK1/2 activation suggesting that activated AhR 
may block IL-6 expression at a stage downstream of p44/p42 activation. 
To identify additional signaling molecules involved in IL-6 regulation, low molecular weight 
inhibitors of protein kinase C, JNKs or p38 MAP kinase family members were tested for their 
inhibitory effects on IL-6 secretion in IL-4+GM-CSF stimulated MM1 cells. None of these 
compounds had any effects on the IL-6 response indicating that these signaling molecules were 
dispensable for IL-6 expression. The negative results with the p38 MAPK inhibitor is in contrast to 
previous studies: in LPS maturated murine dendritic cells induction of IL-6 expression by 
engagement of CD40 was dependent on the activation of p38 MAPK (168). Another study in 
human osteoblasts demonstrated that induction of IL-6 expression by IL-1β was also dependent on 
p38 MAPK (169). It is possible that the involvement of p38 is dependent on the cell type and/or the 
stimulus used. In fact, the regulation of IL-6 gene expression is quite complex. For example, the 
human cervix carcinoma HeLa cell line produced high levels of IL-6 in response to TNF-α and 
 IL-1β while the human colon adenocarcinoma HTM-29 line completely failed to produce IL-6 
although NF-κB p65 and NF-IL6, which are thought to be the main transcription factors involved in 
IL-6 gene activation, were activated in both cell lines (170). In human B-cells, engagement of CD40 
induced IL-6 expression. By using wild-type or mutant IL-6 promoter reporter constructs it was 
shown that the NF-κB, the NF-IL6 as well as the AP-1 regulatory DNA elements were necessary 
for the activation of the IL-6 promoter by CD40 (171). 
In addition to the transcription factors NF-B and NF-IL6, also AP1 was reported to regulate IL-6 
transcription in various systems (19,20). To determine if VAF347 was acting at the level of IL-6 
transcription we performed transient transfections with an IL-6 promoter reporter construct. 
VAF347 could inhibit both PMA and IL-4 + GM-CSF induced IL-6 promoter activity. In contrast, 
VAG005, which is only a weak ligand of AhR, did not interfere with IL-6 promoter activity. These 
results demonstrated that VAF347 interfered with IL-6 expression at the transcriptional level.  
One attractive point of VAF347 intervention was NF-B. A previous study demonstrated that in a 
mouse bone marrow stromal cell line the AhR agonist DMBA abrogated LPS induced IL-6 
synthesis possibly due to reduced binding of NF-κB to its recognition site in the IL-6 promoter in 
the presence of DMBA (161). In addition, NF-κB p65 has been shown to physically interact with 
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AhR (157). Immunoprecipitation experiments intended to examine a possible interaction of AhR 
and NF-κB were performed in cytokine stimulated MM1 cells. However, preliminary data were 
unsuccessful to demonstrate direct interactions between these transcription factors (data not shown). 
Chromatin immunoprecipitation (ChIP) assays were also performed with a NF-κB p65 antibody, 
but no PCR product was observed indicating binding of the transcription factor to its recognition 
sequence on the IL-6 promoter in response to IL-4+GM-CSF (data not shown). It is possible that 
these negative data were due to the poor quality of the antibody used. In addition, two different  
NF-κB inhibitors did not influence IL-6 synthesis in MM1 suggesting no major role of NF-B in 
IL-6 gene regulation. On the other hand, ectopic over-expression of NF-B p65 resulted in 
significantly increased production of IL-6. Overall, the role of NF-B proteins in IL-6 gene 
activation in MM1 cells remains to be more closely investigated. If NF-B plays a major regulating 
role we tend to suggest that it is not involved in the mode of action of VAF347 since in NF-B p65 
overexpressing MM1 cells the compound was as potent to inhibit IL-6 expression as in wild type 
cells (in contrast to NF-IL6 overproducing MM1 cells, see below). 
Another attractive target appeared to be NF-IL6 due to its functional link with ERK1/2 MAPK 
activation: stimulation of human chondrocytes with IL-1β has been shown to induce transcription of 
matrix metalloproteinase-1 (MMP-1) (172). Expression of MMP-1 required phosphorylation of  
NF-IL6 by p44/p42 MAP kinases, since inhibition of MAP kinases with PD98059 abrogated both 
NF-IL6 phosphorylation as well as MMP-1 expression.  
Chromatin immunoprecipitation (ChIP) assays demonstrated that IL-4 + GM-CSF induced the 
binding of NF-IL6 to the IL-6 promoter in MM1 cells. In the presence of VAF347 binding of  
NF-IL6 to the IL-6 promoter was completely absent. These data strongly indicated that VAF347 
blocked IL-6 expression by preventing the interaction of the critical transcription factor NF-IL-6 
with its recognition sequence at the IL-6 promoter. The involvement of NF-IL6 in the mode of 
action of VAF347 was further substantiated in MM1 cells overexpressing NF-IL6. In these cells, 
the inhibitory effects of VAF347 to block IL-6 secretion was greatly (but not completely) 
diminished. 
The ability of VAF347 to block the binding of NF-IL6 to the IL-6 promoter was not due to reduced 
transcription of the NF-IL6 gene, since the expression levels of NF-IL6, NF-κB p65, c-Fos and  
c-Jun after cytokine stimulation or exposure to VAF347 remained constant in MM1 cells. In 
contrast, activation of the p44/p42 MAP Kinases by IFN-γ has been shown to activate the 
transcription of NF-IL6 in a murine macrophage cell line and required activation of STAT1 (173). 
The mechanism by which VAF347 interferes with binding of NF-IL6 is unknown. A possible 
explanation is that AhR not only interacts with DNA but with other signaling molecules involved in 
induction of IL-6 transcription  
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Ectopic over-expression of wild-type NF-IL6 protein partially abolished the inhibitory effect of 
VAF347 on IL-6 expression in both IL-4 + GM-CSF or PMA induced MM1 cells. Over-expression 
of wild-type NF-κB p65 did not alter the inhibitory activity of VAF347 on IL-6 expression. Taken 
together, these results suggested that NF-IL6 was at least partially involved in the events that inhibit 
IL-6 expression by VAF347.  
Since a previous study has demonstrated that NF-IL6 vigorously activated IL-1β gene expression in 
human HeLa cells via a protein-protein tether with the transcription factor PU.1 (158), we examined 
a possible involvement of PU.1 in the signaling events that lead to induction of IL-6 in MM1 by 
silencing of PU.1 gene expression. MM1 cells lacking the PU.1 protein showed a reduced maximal 
IL-6 response in comparison to control cells, while the expression of the CYP1A1 gene was not 
reduced. Due to the specific reduced IL-6 response in MM1 cells lacking PU.1 protein, we suggest 
that PU.1 positively contributes to the induction of the IL-6 promoter. One explanation could be 
that PU.1 enhances transactivation of NF-IL6 in a similar way described for the human IL-1β 
promoter (158). However, in contrast to the IL-1β promoter, no functional PU.1 binding sites have 
been identified in the IL-6 promoter to our knowledge. 
Multiple studies have demonstrated that different cellular concentrations of PU.1 direct distinct cell 
fates, with high concentrations of PU.1 required for macrophage development and lower 
concentrations for B-cell and granulocyte fate adoption (174). Primary human monocytes were 
shown to express only low levels of PU.1, while stimulation of these cells with IL-4 and GM-CSF, 
thus inducing DC differentiation, lead to strong up-regulation of PU.1 (175). In MM1 cells PU.1 
expression was not altered by IL-4 and GM-CSF or VAF347 respectively. 
Interestingly, the inhibitory effect of VAF347 on IL-6 expression in response to IL-4 + GM-CSF 
was abolished in MM1 cells lacking the PU.1 protein. Therefore, PU.1 might possibly be involved 
in the mechanism by which VAF347 interferes with IL-4 + GM-CSF induced IL-6 synthesis. In 
contrast, IL-6 mRNA synthesis in response to PMA was still inhibited by VAF347. These results 
suggest that PMA induced IL-6 expression does not include PU.1 as essential factor. 
Several possibilities exist to explain the molecular events by which VAF347 blocks IL-6 expression 
via activation of AhR. In principle, AhR could act as transcription factor by binding to cis-acting 
elements in regulatory regions or, alternatively, could interact with other factors important for IL-6 
production and disturb their functions. The former possibility calls for the presence of a negatively 
acting AhR binding site in the IL-6 promoter. Up to now several genes have been described to be 
negatively regulated by AhR due to the presence of such a negatively cis-acting XRE element, 
including the cathepsin D, c-Fos and pS2 gene (176-178). However, examination of the IL-6 
promoter has not revealed the presence of any bona fide XRE motifs (data not shown) making this 
possibility less likely. For the second possibility, several scenarios can be envisioned.  
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First, activated AhR may inhibit nuclear translocation of NF-IL6. Second, activated AhR or 
VAF347 itself may inhibit phosphorylation of NF-IL6. Phosphorylation of NF-IL6 has been shown 
to increase its transcriptional activity (14). Another possibility could be that AhR disturbs the 
interaction of transcription factors relevant for induction of IL-6 transcription, for instance by 
inhibiting a possible protein-protein tether between NF-IL6 and PU.1, an interaction which was 
already described for the IL-1β promoter (158). 
 
A summary of the signaling events thought to be involved in the mechanism that drives IL-6 
expression in MM1 is shown in Figure 4.1: Binding of IL-4 and GM-CSF to their receptors lead to 
activation of JAK2 and JAK3 which phosphorylate STAT5 and STAT6.  
 
 
 
Figure 4.1: Signaling events in Monomac1 cells leading to IL-6 production. Stimulation of MM1 
with IL-4 + GM-CSF leads to activation of JAK2/3 resulting in phosphorylation of STAT5/6. STAT 
activation is necessary for subsequent phosphorylation of p42/44 MAP kinases. VAF347 activates AhR 
and leads to reduced binding of NF-IL6 to the IL-6 promoter via an unexplained mechanism(s). One 
attractive possibility may be that activated AhR interferes with PU.1/NF-IL6 heterodimerization or 
NF-IL6 phosphorylation or nuclear translocation resulting in abrogated binding to the IL-6 promoter. 
Alternatively, activated AhR may interfere with the function of AP-1 to co-activate IL-6 gene 
transcription.  
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Consequently, p42 and p44 MAP kinases (ERK1/2) are rapidly activated upon cytokine stimulation. 
The molecular link(s) between activation of STATs and MAP kinase activation remain to be 
determined. Activated ERK1/2 may activate directly or indirectly transcription factors important for 
IL-6 gene activation, such as NF-κB, NF-IL6 or AP1. Support for an indirect function of MAP 
kinases comes from a study in COS cells demonstrating that ERK1/2 phosphorylated p90RSK1 which 
in turn led to activation of NF-κB (179). Since VAF347 had no inhibitory effects on STAT or MAP 
kinase activation, the compound appears to act downstream of MAP kinase activation by interfering 
with DNA binding of NF-IL6. 
 
In summary, we have identified the AhR as the functional molecular target for VAF347. Activation 
of AhR by this compound is essential for mediating the inhibitory effect on IL-6 expression in 
Monomac1 cells. Further data allowed for the identification of NF-IL6 and PU.1 as functionally 
relevant factors which mediate the inhibitory effects of VAF347. Future studies will be designed to 
understand the link between activated AhR and these proteins. Overall, these results highlight the 
AhR as a novel target for the therapeutic manipulation of the immune response. 
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